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1. Theory and experimental procedures    
a. Surprisal analysis  
A detailed discussion of the implementation of surprisal analysis in biology can be found in 1, 2. Briefly, we 
assume that a biological system, including a cell in a tumor, is in a state of minimal free energy subject to 
constraints. In a spontaneous process at a given temperature and pressure the free energy goes down. The 
constraints preclude the free energy from decreasing and so maintain the state. A change in the state is thereby 
described as a change in the constraints. The most stable state of a system is a state of minimal free energy 
without any constraints. Such a state is steady because it cannot change spontaneously. Surprisal analysis uses the 
measured protein expression levels in GBM tumors to identify the constraints that prevent the tumor cells from 
spontaneously reaching a state of minimum of free energy. These constraints define the deviations from that most 
stable steady state. The constraints are recognized and quantified by identifying how the protein expression levels 
change from their value at the steady state due to the presence of those constraints. Thus the biological constraints 
that we identify in the main text are the manifestation of unbalanced processes that take place in the cell.  
For each measured protein the extent of influence of a given unbalanced process on a protein i is defined by our 
procedure of surprisal analysis 1-4. Protein levels can be influenced by more than one unbalanced process. 
Surprisal analysis seeks to represent the expression level of each protein as a sum of terms (sum on the right hand 
side of equation (1) below) representing the constraints.   is an index of the constraints,   1,2,.. . The 
analysis is separately done for every tumor and k is the index of the tumor, here  k =1,..,8 . . SVD is used as a 
mathematical tool to determine two sets of parameters from (logarithm of the) expression level ( )X ki  of protein 
i in the particular tumor k (as described in the sub-section “Calculation of the parameters   and iG  ”):  
1)  The tumor-dependent weights of the constraints  ( )k  (For technical reason it is also called the Lagrange 
multiplier),  
2) The extent of influence of an unbalanced process   on a protein i , iG   . Surprisal analysis identifies weights 
iG   that have the same numerical value for all tumors. 
The two sets of parameters are obtained by fitting equation (1) to the measured protein expression levels 
ln ( ) ln ( ) ( )1
oX k X k G ki i i        (1)        
Here ln ( )oX ki  is the (logarithm of the) expression level in the steady state. As discussed in figure 1 of the text, 
we hypothesize and then validate that the steady state is common for all tumors. The deviation terms are labeled 
as   1,2,.. in order of their decreasing size. When all the constraints are kept in the sum above it is an exact 
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representation of the data and not an approximation. But in practice a few terms suffice to represent the data for 
each protein.  For every constraint we find that  levels of about 100 proteins deviate significantly in either the 
upper ( 0 .0 3iG   )  or lower direction ( 0 .0 3iG    ) from the steady state as shown in Fig. S1 (Lists of those 
proteins and their corresponding  iG   values are included in Additional excel Table SI).  There are some proteins 
that are influenced by several constraints and some that are influenced by only one of the 1,2...7  . For many 
proteins the extent of influence, iG  , is about zero for 1,2...7  ,  meaning that they are mostly players in the 
steady state. Only those proteins with the values 0 .0 3iG    or  0 .0 3iG     were included in the 
classification of biological processes using David database 5  as reported in Tables S1-S8. 
Derivation of the equation (1) 
To obtain Equation (1) in the main text or above, we relate protein concentrations ( )X ki in a tumor k to the 
chemical potential (under constant temperature and pressure) using the fundamental physic-chemical relations 6:      
   
            (2)  
    
The equations above relate the experimental expression level of protein i to its value in the steady state: 
ln ( ) ln ( ) ( ) /i i i
o oX k X k kTi             (3) 
Given the experimental data  we seek to obtain ( )oX ki , which is expected protein expression level at the steady 
state, as well as ( ) /i i
o kT  , which is the deviation from the steady state. Equation (3) represents the changes 
in the chemical potential for each measured protein. From it we can get the change in the free energy of the 
proteomic system as a whole when the constraint(s) are changing and so therefore do the expression levels of the 
proteins, ( ( )( ) 0i i ii
oG X k      ).  To calculate the steady state expression levels, ( )oX ki , and 
deviations thereof, (i  io) / kT , we use a procedure described in 2.  
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In the numerical procedure it is convenient to represent the steady state level as Xi
o(k)  exp Gi00(k)    2. 
( )0 k  represents the weight of the steady state term in every measured cell. The weight of the proteins when all 
cellular processes are balanced are described by 0G i . The deviations from the steady state are the terms labelled 
as 1,2  in the order of their decreasing weight as given by ( )k . The extent of influence of a given unbalanced 
process 1,2...  on a protein i, is given by Gi . Thus a change in the chemical potential of protein i, 
( ) /oi i kT  , due to the constraints 1,2...  is represented by ( )1 G ki     .  
The proteins are correlated due to the constraints. In each constraint all the participating proteins act collectively. 
This is because each given constraint influences the levels of specific proteins causing a deviation from the steady 
state limit.  That subset of specific proteins that deviate in a similar manner (up or down to the reference limit)  are 
analyzed to give biological meaning to the constraint as described below. 
Calculation of the parameters   and Gi  We want to fit the sum of the terms as shown on the right-hand 
side of equation (1) to the logarithm of the measured expression level of protein i in a tumor k. This has to be 
repeated for every tumor.  We use the singular value decomposition  2 (SVD, and more below) as a method for 
diagonalizing a matrix that includes mean values of (the logarithm of) protein intensities at tumor k.  
SVD    To apply the mathematical procedure of  SVD we generate a matrix Y utilizing the natural 
logarithm of the protein intensity levels, as measured 2. The columns of Y are (logarithms of) measurements for a 
particular tumor. The rows of Y are (logarithms of) measurements for a particular protein. Using  SVD, we construct 
two square (and symmetric) matrices. The first one is: YT Y . To determine constraints we diagonalize this matrix: 
2 , 0,1, 2, .., A-1T     Y Y   .  is an eigenvector and 2 is an eigenvalue of the matrix TY Y
. The components of the vector  provide the weights of the constraint   at each of the distance ranges r. The 
maximal number of non-zero eigenvalues  is A, where A is the smaller of the dimensions of the matrix Y (here 
A=8 since we analye 8 GBM tumors).  The mathematically exact statement is that A is the rank of the matrix Y. 
The maximal number of possible constraints is equal to A-1 2.   
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To determine the iG  we generate a second square matrix: TYY 2. This conjugated matrix has the same value of 
eigenvalues 2 : YYTG 2 G ,  0,1,2,..,A-1.   G  is a column vector of ~1800 components, each 
component corresponding to a measured protein in the constraint   .  
Biological classification   Lists of the proteins that are influenced significantly either by the unbalanced processes 
(Fig.S1 Theoretical approach), or principle components (PCA, Fig.S7) or clusters (k-means clustering, Table S14) 
were generated. These lists were classified according to biological categories using David database 5.  Biological 
categories were considered as statistically significant enriched groups if they had EASE score and Benjamini 
correction 5 values 0.05. 
b. Implementation of Surprisal analysis to data measured by the iTRAQ technology 
Surprisal analysis provides a theoretical expression for the concentration 2. We show how Surprisal analysis can 
be implemented for iTRAQ proteomic measurements, where protein intensities rather than protein concentrations 
are generated as an output. As shown below unbalanced biological processes are identified in a similar fashion 
from either protein copy numbers or protein intensities datasets.    
In iTRAQ the expected ion peak is related to the observed ion peak through a set of multiplicative factors. These 
include the technical biological factors but also such aspects as the relation of a peptide concentration to the 
associated protein concentration, etc 7. It is therefore suggestive to recast the observed data in a logarithmic form 
so that the effects are additive, see for example equation (4) in 7. When we use a logarithmic form the factors 
enter in an additive fashion.  
Let  Xi  be the intensity (abundance) of protein i as determined from the observed value of the corresponding 
peptides. That intensity is related to the concentration of protein i.Yi , as a  
ln ln lni i innY X F                                                                                       (4) 
where the sum is over all the relevant factors, representing mass spectral experimental uncertainties,  as listed e.g., 
in Table 2 of Hill et al 7. As in Karpeivitch et al  and Hill et al we take it that the terms in equation (4) are 
uncorrelated. In general and in the case we analyze here there are different samples so that there is a label  on the 
intensities corresponding to the different conditions, here different GBM tumors - k. 
For lnYi  we use  equation (1) of the main text: 

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ln ( ) ln ( ) ( ) ln1i inn
oX k X k G k Fi i                           (5) 
Since the majority of the factors in Hill et al.7 are condition independent, the sum ln inn F  (representing 
different iTRAQ factors as presented in table 2 in 7 ) will be included mostly in the zero eigenvector of the 
Surprisal analysis. The condition dependent uncertainty in other eigenvectors is estimated as described below and 
in Gross et al.8.  
We can rewrite the equation (5): 
 ln ( ) (ln ( ) ln ) ( )1i inn
oX GBM X k F G ki i         
The sum (ln ( ) ln )inn
oX k Fi   will be fitted mostly by the 0’th term of Surprisal analysis (generated from the 
first eigenvectors of the SVD analysis 2 and denoted asGi00 ). The condition/tumor dependent uncertainty for 
the terms representing biological constraints can be directly  translated 8 to an error in the lambdas. In the theory, 
see for example 2, the lambdas are Lagrange multipliers. Each multiplier is a measure by how much the ongoing 
process reduces the entropy. When a multiplier vanishes the process is balanced. When the error ( )k  in a 
particular ( )k  is comparable to it, the process need not be included. 
In summary, we represent the fitted intensities as 
ln ( ) ln ( ) ( )1
oX k X k G ki i i        
where the sum is restricted to such ( )k  whose error is small ( ) ( )k k   . 
c. Error determination in surprisal analysis. 
The experiment was performed in four biological replicates and the standard deviation, s.d. was taken for each 
expression level when given. Surprisal analysis was performed 3 times.  Once for the mean values of the proteins, 
once for the mean values of the protein expression . .s d  for each measured protein, and once for the mean of the 
protein expression . .s d  Proteins with large . .s d , so that their values of ( . ) 0m ean s d  , were excluded from 
the analysis. Thus three values for the weights ( )r were obtained. Results of Suprisal analysis presented in the 
article are the mean values of the corresponded parameters . .s d  8 
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d. Minor unbalanced processes 
The higher index constraints usually exhibit smaller influences on protein/transcript expression levels 1, 2.  
Constraints 5, 6 and 7 were found to influence significantly GBM 8, 15, 26 and 6. To validate the significance of 
these last constraints we analyzed a smaller data set that included only those four GBM tumors.  Surprisal analysis 
of the smaller matrix showed that the stable state term remains the same, to within experimental error, as when it is 
calculated using all 7 tumors (Fig. S5a).   When only the dataset for the four tumors is analyzed, 3 constraints are 
readily resolved.  Those constraints correspond roughly to the constraints 5-7 when the data for all tumors is 
analyzed.  This is shown in Fig. S5b,c and in Fig.S6, and validates that we do in fact resolve all 7 constraints when 
analyzing the whole data set.  Fig. S5d illustrates the influence of constraints 5-7 on a couple of different proteins.  
These results confirm the significance of the minor unbalanced processes in GBM tumors and also provide an 
illustration of the robustness of surprisal analysis.  
The minor constraints provide a higher resolution for differentiation of the 8 GBM tumors (Fig. S5 and Fig. 
S6). For example, the constraint 5    distinguishes between GBM6 and GBM15 (Fig. S6).  This constraint 
increases the expression of key proteins participating in Ras/MAPK signaling, as well as in glycolysis through 
oxidative phosphorylation in GBM6.   Proteins that are influenced include multiple ATP synthases, aldolase A, 
LDHB, IDH2, pMAPK3, pP38 (MAPK14), and pMAPK12 (Table S6). 
e. Experimental procedure and processing of the raw proteomic data 
Experimental procedure 
Detailed description of all experimental procedures related to the iTRAQ proteomic dataset is described in detail 
in 9. Here we provide essential information for understanding of the current paper.  GBM xenografts were labeled 
using the iTRAQ 8plex channels as follows: 113-GBM6; 114-GBM8; 115-GBM10; 116-GBM12; 117-GBM15; 
118-GBM26; 119-GBM39; and 121-GBM59 throughout all four biological replicates. GBM6 biological replicate 
1 and biological replicate 4 were analyzed in the place of biological replicate 2 and 3 respectively. 
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The way that the iTRAQ intensities were generated as follows; the raw iTRAQ8plex intensities were summed for 
all peptides (and all instances of each peptide) derived from a particular protein were quantified. This was also 
done for all instances that a peptide or phosphotyrosine peptide was quantified. For either protein expression 
quantification or phosphotyrosine quantification this was carried out within each analysis (i.e. for each biological 
replicate) and then across all 4 biological replicates. The implication of this is that the peptides that have a greater 
intensity are weighted more towards the total iTRAQ8plex intensity readout for each given protein or 
phosphotyrosine peptide. This effectively reduces the impact of instrumental noise on the resulting intensities. 
These raw values were then normalized to the iTRAQ8plex ratios to account for protein loading within each of 
the iTRAQ8plex channels. These final intensities can then also be expressed as ratios either relative for the mean 
of all 8 channels or expressed as a ratio relative to a single channel. 
Processing of the raw proteomic data 
A decoy database search strategy was used to estimate the false discovery rate (FDR), defined as the percentage 
of decoy proteins identified against the total protein identification. The FDR was calculated by searching the 
spectra against the NCBI nonredundant Homo sapiens decoy database. Before filtering the protein expression data 
(explained above), the protein level FDR was calculated at 1%, corresponding to 2357, 2122, 2434, and 2222 
proteins in biological replicates 1, 2, 3, and 4 respectively. After application of the above filter criteria, the 
estimated FDR value was <1% (at the protein level) for each of the biological replicates analyzed, indicating a 
high reliability in the proteins identified. Peptide summaries were exported from ProteinPilotTM and isotope 
correction and relative quantification was calculated in Excel. Based on the biological variation, observed proteins 
with iTRAQ ratios below 0.75 were considered to be reduced in expression and proteins with iTRAQ ratios above 
1.25 were considered to be increased in expression. 
For the phosphotyrosine data a Mascot score cutoff of 25 was used to initially filter the data (this corresponds to a 
FDR cutoff of 1%). We further interrogated the data by manually validating the spectra and only included spectra 
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where we were sure of the peptide sequence and the location of the phosphorylation site on the peptide sequence. 
All validated mass spectra for the phosphotyrosine peptides are included in the original manuscript. 
The overlapping data was discussed in 9. The overlapping phosphotyrosine peptides and proteins quantified across 
each biological replicate. As each analysis included all 8 of the GBM xenograft lines there were no instances of 
missing data. There were only instances of peptides or phosphorylation sites that were not quantified across more 
than 1 biological replicate 9. 
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2. Biological classification of the proteins participating in the Unbalanced processes 1,2,...7   
Only statistically significant biological groups (EASE score and Benjamini correction values  0.05) 
were included in biological interpretation of the constraints. Similar statistical considerations were applied to all 
unbalanced processes. A more complete list of proteins that are influenced significantly by the different 
constraints is provided in the Additional Table SI. Tables S1-S8 include both proteins with altered expression 
and altered phosphorylation. To distinguish between proteins with altered expression and altered phosphorylation 
in every constraint see Additional Table SI.  
Table S1. GO classification of the proteins influenced mostly by the Steady state term. 
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0006412~translation 65 4.33E-
30 
EIF6, EIF5, EIF5B, QARS, RPS3, RPS3A, RPLP0, RPL10, RPL11, 
RPL12, TPR, RPS27A, CARS, YARS, DARS, EIF2S3, EIF4G1, EIF4G2, 
TARS, RPS19, RPS17, RARS, EIF2S1, RPS14, EIF4A2, EIF4A1, RPS12, 
HARS, FARSB, FARSA, NACA, PABPC4, RPS15A, RPL36, RPL38, 
VARS, EIF3C, EIF3D, RPS26, EIF3A, RPS28, EIF3B, MRPL12, EIF3G, 
EIF3H, EIF3E, RPL9, LARS, EIF3K, EIF3I, RPL4, RPS20, RPS21, 
RPS24, MARS, RPSA, EEF1A1, RRBP1, EPRS, DENR, ETF1, RPS5, 
RPS7, RPL23, TSFM 
9.62E-27 
GO:0008380~RNA splicing 51 9.45E-
22 
SNRPD3, LSM7, SNRPD1, SNRPD2, SYNCRIP, SART1, PNN, DDX23, 
RBM8A, PRMT5, SRRM2, PCBP1, U2AF1, LUC7L3, SNRPA1, 
PPP2R1A, EFTUD2, PTBP1, MBNL1, HNRNPR, EIF4A3, SNRNP200, 
SNRPB, RBM39, SNRPE, NHP2L1, STRAP, TRA2B, SF3B4, SF3B3, 
SF3B2, PRPF19, HNRNPL, HNRNPA3, HNRNPM, SF3B1, DDX46, 
PPP2CA, PRPF8, DHX15, HNRNPD, PABPC1, DHX9, RNPS1, DDX5, 
SF3A2, SF3A1, HNRNPH3, HNRNPUL1, RBM14, PUF60 
1.05E-18 
GO:0016071~mRNA 
metabolic process 
58 9.97E-
22 
SNRPD3, LSM7, SNRPD1, SNRPD2, SYNCRIP, HNRPLL, SART1, 
PNN, DCPS, APP, DNAJB11, DDX23, RBM8A, PRMT5, SRRM2, 
PCBP1, U2AF1, LUC7L3, SNRPA1, EFTUD2, PTBP1, MBNL1, 
HNRNPR, EIF4A3, SNRNP200, SNRPB, CPSF6, RBM39, SNRPE, 
NHP2L1, STRAP, TRA2B, RNH1, SF3B4, SF3B3, SF3B2, PRPF19, 
HNRNPL, HNRNPA3, HNRNPM, SF3B1, DDX46, PRPF8, EIF3E, 
DHX15, HNRNPD, PABPC1, DHX9, UPF1, ELAVL1, RNPS1, DDX5, 
SF3A2, SF3A1, HNRNPH3, HNRNPUL1, RBM14, PUF60 
7.38E-19 
GO:0006397~mRNA 
processing 
52 3.98E-
20 
SNRPD3, LSM7, SNRPD1, SNRPD2, SYNCRIP, HNRPLL, SART1, 
PNN, APP, DDX23, RBM8A, PRMT5, SRRM2, PCBP1, U2AF1, 
LUC7L3, SNRPA1, EFTUD2, PTBP1, MBNL1, HNRNPR, EIF4A3, 
SNRNP200, SNRPB, CPSF6, RBM39, SNRPE, NHP2L1, STRAP, 
TRA2B, SF3B4, SF3B3, SF3B2, PRPF19, HNRNPL, HNRNPA3, 
HNRNPM, SF3B1, DDX46, PRPF8, DHX15, HNRNPD, PABPC1, 
DHX9, RNPS1, DDX5, SF3A2, SF3A1, HNRNPH3, HNRNPUL1, 
RBM14, PUF60 
2.21E-17 
GO:0006396~RNA 
processing 
67 3.51E-
19 
SNRPD3, LSM7, SNRPD1, SNRPD2, SYNCRIP, HNRPLL, SART1, 
PNN, APP, DDX17, DDX23, RBM8A, PCBP1, PRMT5, SRRM2, U2AF1, 
RPL11, LUC7L3, SNRPA1, PPP2R1A, EFTUD2, PTBP1, MBNL1, 
HNRNPR, EIF4A3, PA2G4, RPS19, RPS17, RPS14, SNRNP200, SNRPB, 
CPSF6, RBM39, SNRPE, HSD17B10, NHP2L1, STRAP, TRA2B, 
PABPC4, SF3B4, SF3B3, SF3B2, HNRNPA3, PRPF19, HNRNPL, SRRT, 
HNRNPM, SF3B1, RPS28, DDX46, PPP2CA, PRPF8, HNRNPD, 
DHX15, PABPC1, RPS24, DHX9, RNPS1, DDX5, SF3A2, SF3A1, FBL, 
RPS7, HNRNPH3, HNRNPUL1, RBM14, PUF60 
1.56E-16 
GO:0000398~nuclear mRNA 
splicing, via spliceosome 
34 1.83E-
17 
NHP2L1, TRA2B, SNRPD3, LSM7, SNRPD1, SNRPD2, SF3B4, SF3B3, 
SF3B2, HNRNPL, HNRNPA3, HNRNPM, SF3B1, DDX23, RBM8A, 
PRMT5, PRPF8, PCBP1, HNRNPD, U2AF1, DHX9, SNRPA1, EFTUD2, 
PTBP1, RNPS1, MBNL1, SF3A2, SF3A1, HNRNPR, HNRNPH3, 
HNRNPUL1, SNRNP200, SNRPB, SNRPE 
6.79E-15 
GO:0000375~RNA splicing, 
via transesterification 
reactions 
34 1.83E-
17 
NHP2L1, TRA2B, SNRPD3, LSM7, SNRPD1, SNRPD2, SF3B4, SF3B3, 
SF3B2, HNRNPL, HNRNPA3, HNRNPM, SF3B1, DDX23, RBM8A, 
PRMT5, PRPF8, PCBP1, HNRNPD, U2AF1, DHX9, SNRPA1, EFTUD2, 
6.79E-15 
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PTBP1, RNPS1, MBNL1, SF3A2, SF3A1, HNRNPR, HNRNPH3, 
HNRNPUL1, SNRNP200, SNRPB, SNRPE 
GO:0000377~RNA splicing, 
via transesterification 
reactions with bulged 
adenosine as nucleophile 
34 1.83E-
17 
NHP2L1, TRA2B, SNRPD3, LSM7, SNRPD1, SNRPD2, SF3B4, SF3B3, 
SF3B2, HNRNPL, HNRNPA3, HNRNPM, SF3B1, DDX23, RBM8A, 
PRMT5, PRPF8, PCBP1, HNRNPD, U2AF1, DHX9, SNRPA1, EFTUD2, 
PTBP1, RNPS1, MBNL1, SF3A2, SF3A1, HNRNPR, HNRNPH3, 
HNRNPUL1, SNRNP200, SNRPB, SNRPE 
6.79E-15 
GO:0006414~translational 
elongation 
28 4.97E-
17 
RPS15A, RPL36, RPL38, VARS, RPS3, RPS26, RPS28, RPS3A, RPLP0, 
RPL9, RPL10, RPL11, RPL12, RPL4, RPS20, RPS21, RPS27A, RPS24, 
RPSA, EEF1A1, RPS5, RPS7, RPS19, RPL23, RPS17, RPS14, TSFM, 
RPS12 
1.58E-14 
GO:0051443~positive 
regulation of ubiquitin-
protein ligase activity 
24 6.85E-
17 
SKP1, PSMA7, UBE2N, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, 
PSMD12, PSMC4, PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, 
PSMD2, PSMD4, PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8 
3.09E-14 
GO:0051438~regulation of 
ubiquitin-protein ligase 
activity 
25 7.97E-
17 
PSMA7, PSMF1, PSMB1, PSMB3, PSMD1, PSMD2, PSMD4, PSMD5, 
PSMD6, PSMD7, BUB3, RPS27A, PSMD8, SKP1, UBE2N, PSMC6, 
PSMC5, PSMD13, PSMD12, PSMC4, PSMD11, PSMA4, PSMC2, 
PSMC1, PSME3 
2.74E-14 
GO:0051439~regulation of 
ubiquitin-protein ligase 
activity during mitotic cell 
cycle 
24 9.8E-17 SKP1, PSMA7, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, PSMD12, 
PSMC4, PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, PSMD2, 
PSMD4, PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8, BUB3 
2.46E-14 
GO:0031145~anaphase-
promoting complex-
dependent proteasomal 
ubiquitin-dependent protein 
catabolic process 
23 1.59E-
16 
PSMA7, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, PSMD12, PSMC4, 
PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, PSMD2, PSMD4, 
PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8, BUB3 
2.24E-14 
GO:0051436~negative 
regulation of ubiquitin-
protein ligase activity during 
mitotic cell cycle 
23 1.59E-
16 
PSMA7, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, PSMD12, PSMC4, 
PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, PSMD2, PSMD4, 
PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8, BUB3 
2.24E-14 
GO:0051351~positive 
regulation of ligase activity 
24 1.96E-
16 
SKP1, PSMA7, UBE2N, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, 
PSMD12, PSMC4, PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, 
PSMD2, PSMD4, PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8 
4.11E-14 
GO:0051340~regulation of 
ligase activity 
25 2.1E-16 PSMA7, PSMF1, PSMB1, PSMB3, PSMD1, PSMD2, PSMD4, PSMD5, 
PSMD6, PSMD7, BUB3, RPS27A, PSMD8, SKP1, UBE2N, PSMC6, 
PSMC5, PSMD13, PSMD12, PSMC4, PSMD11, PSMA4, PSMC2, 
PSMC1, PSME3 
3.8E-14 
GO:0051444~negative 
regulation of ubiquitin-
protein ligase activity 
23 3.31E-
16 
PSMA7, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, PSMD12, PSMC4, 
PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, PSMD2, PSMD4, 
PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8, BUB3 
5.28E-14 
GO:0051352~negative 
regulation of ligase activity 
23 3.31E-
16 
PSMA7, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, PSMD12, PSMC4, 
PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, PSMD2, PSMD4, 
PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8, BUB3 
5.28E-14 
GO:0051437~positive 
regulation of ubiquitin-
protein ligase activity during 
mitotic cell cycle 
23 4.73E-
16 
SKP1, PSMA7, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, PSMD12, 
PSMC4, PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, PSMD2, 
PSMD4, PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8 
6.58E-14 
GO:0031398~positive 
regulation of protein 
ubiquitination 
25 5.28E-
16 
FKBP1A, PSMA7, PSMF1, PSMB1, PSMB3, PSMD1, PSMD2, PSMD4, 
PSMD5, PSMD6, PSMD7, RPS27A, PSMD8, SKP1, UBE2N, PSMC6, 
PSMC5, PSMD13, PSMD12, PSMC4, PSMD11, PSMA4, PSMC2, 
PSMC1, PSME3 
7.7E-14 
GO:0031397~negative 
regulation of protein 
ubiquitination 
23 3.84E-
15 
PSMA7, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, PSMD12, PSMC4, 
PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, PSMD2, PSMD4, 
PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8, BUB3 
5.08E-13 
GO:0031396~regulation of 
protein ubiquitination 
26 4.45E-
15 
FKBP1A, PSMA7, PSMF1, PSMB1, PSMB3, PSMD1, PSMD2, PSMD4, 
PSMD5, PSMD6, PSMD7, BUB3, RPS27A, PSMD8, SKP1, UBE2N, 
PSMC6, PSMC5, PSMD13, PSMD12, PSMC4, PSMD11, PSMA4, 
PSMC2, PSMC1, PSME3 
5.48E-13 
GO:0031400~negative 
regulation of protein 
modification process 
28 4.81E-
15 
FKBP1A, PSMA7, PSMF1, PSMB1, PSMB3, PPP2CA, PSMD1, PSMD2, 
PSMD4, PSMD5, PSMD6, PSMD7, BUB3, RPS27A, PSMD8, PPP2R1A, 
YWHAB, PSMC6, PSMD13, PSMC5, PSMD12, PSMC4, PSMD11, BAX, 
PSMA4, PSMC2, PSMC1, PSME3 
5.58E-13 
GO:0032268~regulation of 
cellular protein metabolic 
process 
54 4.58E-
14 
HSP90AB1, METAP1, EIF5, EIF5B, APP, PRKAR2A, RBM8A, PSMD1, 
PSMD2, PSMD4, PSMD5, PSMD6, PSMD7, PSMD8, RPS27A, DBNL, 
PPP2R1A, SKP1, UBE2N, EIF4G1, SARNP, MAPK1, EIF4A3, EIF4G2, 
PA2G4, PSMA4, EIF2S1, EIF4A2, F2, PSME3, FKBP1A, PSMA7, 
PSMF1, EIF3B, PSMB1, EIF3H, PSMB3, PPP2CA, EIF3E, EIF3K, 
5.09E-12 
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BUB3, UPF1, YWHAB, ETF1, RPS5, PSMC6, PSMD13, PSMC5, 
PSMD12, PSMC4, PSMD11, BAX, PSMC2, PSMC1 
GO:0043161~proteasomal 
ubiquitin-dependent protein 
catabolic process 
24 6.03E-
13 
ERLIN2, PSMA7, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, 
PSMD12, PSMC4, PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, 
PSMD2, PSMD4, PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8, 
BUB3 
6.38E-11 
GO:0010498~proteasomal 
protein catabolic process 
24 6.03E-
13 
ERLIN2, PSMA7, PSMF1, PSMC6, PSMD13, PSMC5, PSMB1, 
PSMD12, PSMC4, PSMD11, PSMB3, PSMC2, PSMA4, PSMD1, PSMC1, 
PSMD2, PSMD4, PSME3, PSMD5, PSMD6, PSMD7, RPS27A, PSMD8, 
BUB3 
6.38E-11 
 
Table S2. GO classification of the proteins influenced by the unbalanced process   1 
Increased protein expression in GBMwt+ and GBM EGFRVIII tumors due to   1 
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0007010~cytoskeleton 
organization 
21 1.4E-11 ALDOA, ARHGEF2, CNN3, TLN2, CRYAB, BCAR1, ABI2, 
ACTN1, ITGB1, WAS, LLGL1, ACTG1, EPB41L2, TUBB, 
ERBB2IP, FGFR1OP, CFL1, MAP2, FGD5, ABL2, DBN1 
1.4E-08 
GO:0030036~actin cytoskeleton 
organization 
15 4.7E-10 ALDOA, ARHGEF2, CNN3, BCAR1, ABI2, ACTN1, WAS, 
ITGB1, LLGL1, ACTG1, EPB41L2, CFL1, FGD5, DBN1, ABL2 
2.4E-07 
GO:0030029~actin filament-
based process 
15 1.1E-09 ALDOA, ARHGEF2, CNN3, BCAR1, ABI2, ACTN1, WAS, 
ITGB1, LLGL1, ACTG1, EPB41L2, CFL1, FGD5, DBN1, ABL2 
3.7E-07 
GO:0007015~actin filament 
organization 
9 3.3E-08 ALDOA, ARHGEF2, BCAR1, CFL1, ABI2, ACTN1, ABL2, WAS, 
DBN1 
8.5E-06 
GO:0007173~epidermal growth 
factor receptor signaling 
pathway 
6 1.3E-06 EGFR, EPS15, ERBB2IP, BCAR1, CBL, GAB1 2.6E-04 
GO:0007169~transmembrane 
receptor protein tyrosine kinase 
signaling pathway 
11 3.4E-06 EGFR, EPS15, DDR1, EPHA4, MPZL1, ERBB2IP, BCAR1, CBL, 
GAB1, PTPRA, STAT3 
5.7E-04 
GO:0006793~phosphorus 
metabolic process 
21 9.2E-06 EGFR, FYB, DBNL, LYN, INPPL1, PTPRZ1, HCK, PTPRA, ABI2, 
MAPK11, FER, ACP1, DDR1, MAPK1, EPHA4, MAPK12, GAB1, 
MAP2, NDUFS8, CFL1, ABL2 
1.3E-03 
GO:0006796~phosphate 
metabolic process 
21 9.2E-06 EGFR, FYB, DBNL, LYN, INPPL1, PTPRZ1, HCK, PTPRA, ABI2, 
MAPK11, FER, ACP1, DDR1, MAPK1, EPHA4, MAPK12, GAB1, 
MAP2, NDUFS8, CFL1, ABL2 
1.3E-03 
GO:0006468~protein amino acid 
phosphorylation 
17 1.3E-05 EGFR, FYB, DBNL, LYN, HCK, PTPRA, ABI2, MAPK11, FER, 
DDR1, EPHA4, MAPK1, MAPK12, MAP2, CFL1, GAB1, ABL2 
1.6E-03 
GO:0006928~cell motion 14 2.4E-05 CCDC88A, BCAR1, ANXA1, ABI2, YWHAE, ITGB1, STAT3, 
VCL, ACTG1, EPHA4, TUBB, ROBO1, CFL1, HSPB1 
2.6E-03 
GO:0007167~enzyme linked 
receptor protein signaling 
pathway 
12 2.4E-05 EGFR, EPS15, DDR1, EPHA4, MPZL1, ERBB2IP, BCAR1, 
ZFYVE16, CBL, GAB1, PTPRA, STAT3 
2.5E-03 
GO:0016310~phosphorylation 18 3.2E-05 EGFR, FYB, DBNL, LYN, HCK, PTPRA, ABI2, MAPK11, FER, 
DDR1, EPHA4, MAPK1, MAPK12, MAP2, NDUFS8, CFL1, 
GAB1, ABL2 
2.9E-03 
GO:0018108~peptidyl-tyrosine 
phosphorylation 
5 2.9E-04 DDR1, LYN, ABI2, FER, ABL2 2.4E-02 
GO:0006096~glycolysis 5 3.1E-04 ALDOA, GPI, LDHB, ALDOC, ENO1 2.4E-02 
GO:0007155~cell adhesion 15 3.2E-04 EGFR, RPSA, INPPL1, TLN2, BCAR1, CTNND2, ACTN1, 
CTNND1, FER, ITGB1, VCL, DDR1, ERBB2IP, ROBO1, ABL2 
2.3E-02 
GO:0022610~biological 
adhesion 
15 3.3E-04 EGFR, RPSA, INPPL1, TLN2, BCAR1, CTNND2, ACTN1, 
CTNND1, FER, ITGB1, VCL, DDR1, ERBB2IP, ROBO1, ABL2 
2.2E-02 
GO:0018212~peptidyl-tyrosine 
modification 
5 3.4E-04 DDR1, LYN, ABI2, FER, ABL2 2.1E-02 
GO:0032989~cellular 
component morphogenesis 
11 4.3E-04 EGFR, ACTG1, EPHA4, ARHGEF2, ERBB2IP, PTPRZ1, ROBO1, 
CFL1, ITGB1, SLITRK5, LLGL1 
2.5E-02 
GO:0009719~response to 
endogenous stimulus 
11 5.0E-04 MAPK1, A2M, LYN, CRYAB, ALDOC, BCAR1, GAB1, CFL1, 
PTPRA, IDH1, STAT3 
2.8E-02 
GO:0006006~glucose metabolic 
process 
7 6.8E-04 ALDOA, GPI, LDHB, CRYAB, ALDOC, PHKA1, ENO1 3.6E-02 
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Decreased protein expression in GBMwt+ and GBM EGFRVIII tumors  
There are no statistically significant biological categories. 
 
Table S3. GO classification of the proteins influenced by the unbalanced process 2   
Increased protein expression in GBM39 and 59 due to 2   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0030029~actin filament-based 
process 
16 2.4E-09 MYL6, ALDOA, ARHGEF2, TLN1, ACTA1, MYL1, ACTN1, 
MYH4, MYH9, TPM1, ACTG1, EZR, PTK2B, FGD5, DBN1, 
ABL2 
3.1E-06 
GO:0030036~actin cytoskeleton 
organization 
13 5.8E-07 ALDOA, TLN1, ARHGEF2, ACTA1, ACTN1, MYH9, TPM1, 
ACTG1, EZR, PTK2B, FGD5, DBN1, ABL2 
3.9E-04 
GO:0007015~actin filament 
organization 
8 2.8E-06 ALDOA, ARHGEF2, EZR, ACTA1, PTK2B, ACTN1, ABL2, 
DBN1 
1.2E-03 
GO:0006928~cell motion 17 3.2E-06 TLN1, PODXL, ANXA1, MYH9, VAV2, TPM1, STAT3, TPM4, 
VCL, TPM3, ACTG1, CD44, PTK2B, HSPB1, MSN, THBS1, 
GAP43 
1.1E-03 
GO:0007173~epidermal growth factor 
receptor signaling pathway 
6 3.7E-06 EGFR, EPS15, PTK2B, CBL, GAB1, SHC1 9.9E-04 
GO:0007155~cell adhesion 20 8.3E-06 DCBLD2, EGFR, INPPL1, TNC, ACTN1, CD99, MYH9, CD151, 
PXN, VCL, LGALS3BP, EZR, COL14A1, CD44, PTK2B, 
COL6A3, COL6A2, MSN, THBS1, ABL2 
1.9E-03 
GO:0022610~biological adhesion 20 8.5E-06 DCBLD2, EGFR, INPPL1, TNC, ACTN1, CD99, MYH9, CD151, 
PXN, VCL, LGALS3BP, EZR, COL14A1, CD44, PTK2B, 
COL6A3, COL6A2, MSN, THBS1, ABL2 
1.6E-03 
GO:0030030~cell projection 
organization 
14 1.7E-05 EGFR, UCHL1, CLU, GJA1, MYH9, VAV2, HPRT1, TPM1, 
VCL, CD44, PTK2B, FGD5, SLITRK5, GAP43 
2.9E-03 
GO:0007010~cytoskeleton 
organization 
15 2.4E-05 ALDOA, ARHGEF2, TLN1, CAV1, ACTA1, ACTN1, MYH9, 
TPM1, ACTG1, EZR, PTK2B, FGFR1OP, FGD5, DBN1, ABL2 
3.5E-03 
GO:0030048~actin filament-based 
movement 
5 4.1E-05 MYL6, MYL1, MYH4, MYH9, TPM1 5.5E-03 
GO:0070252~actin-mediated cell 
contraction 
4 5.1E-05 MYL6, MYL1, MYH4, TPM1 6.2E-03 
GO:0030049~muscle filament sliding 4 5.1E-05 MYL6, MYL1, MYH4, TPM1 6.2E-03 
GO:0033275~actin-myosin filament 
sliding 
4 5.1E-05 MYL6, MYL1, MYH4, TPM1 6.2E-03 
GO:0030705~cytoskeleton-dependent 
intracellular transport 
6 8.3E-05 MYL6, MYL1, UCHL1, MYH4, MYH9, TPM1 9.2E-03 
GO:0042692~muscle cell 
differentiation 
8 8.5E-05 ACTG1, CAST, ACTA1, TNC, LGALS1, MYH9, CAPN2, TPM1 8.7E-03 
GO:0051146~striated muscle cell 
differentiation 
7 1.1E-04 ACTG1, CAST, ACTA1, TNC, MYH9, CAPN2, TPM1 1.1E-02 
GO:0000768~syncytium formation by 
plasma membrane fusion 
4 1.3E-04 CAST, CD44, MYH9, CAPN2 1.2E-02 
GO:0007169~transmembrane receptor 
protein tyrosine kinase signaling 
pathway 
10 1.4E-04 EGFR, EPS15, PTK2B, CBL, GAB1, ABI1, SHC1, STAT3, 
EPHA2, PXN 
1.2E-02 
GO:0032989~cellular component 
morphogenesis 
13 1.6E-04 EGFR, ARHGEF2, ACTA1, UCHL1, CLU, GJA1, HPRT1, 
MYH9, TPM1, ACTG1, EZR, SLITRK5, GAP43 
1.3E-02 
GO:0007167~enzyme linked receptor 
protein signaling pathway 
12 1.8E-04 EGFR, EPS15, PTK2B, ZFYVE16, CBL, GAB1, COL1A2, ABI1, 
SHC1, STAT3, EPHA2, PXN 
1.3E-02 
GO:0006949~syncytium formation 4 2.1E-04 CAST, CD44, MYH9, CAPN2 1.5E-02 
GO:0006007~glucose catabolic 
process 
5 7.0E-04 ALDOA, GPI, LDHB, ALDOC, ENO1 3.5E-02 
GO:0030030~cell projection 
organization 
10 1.0E-03 EGFR, EPHA4, CCDC88A, PTPRZ1, ROBO1, MAP2, ABI2, 
FGD5, SLITRK5, VCL 
4.8E-02 
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GO:0043405~regulation of MAP 
kinase activity 
8 2.2E-04 EGFR, SPRY1, CAV1, PTK2B, GAB1, SHC1, THBS1, SPRY4 1.5E-02 
GO:0006936~muscle contraction 8 3.6E-04 MYL6, ALDOA, ACTA1, MYH1, MYL1, MYH4, GJA1, TPM1 2.3E-02 
GO:0030182~neuron differentiation 13 4.0E-04 EGFR, UCHL1, CLU, GJA1, HPRT1, RTN1, EPHA2, STAT3, 
CD44, PTK2B, SLITRK5, TUBB3, GAP43 
2.4E-02 
GO:0034329~cell junction assembly 5 4.2E-04 TLN1, PTK2B, GJA1, ACTN1, VCL 2.4E-02 
GO:0032507~maintenance of protein 
location in cell 
5 4.2E-04 TLN1, CAV1, EZR, PDIA3, FGFR1OP 2.4E-02 
GO:0007517~muscle organ 
development 
9 4.9E-04 MYL6, CAV1, ACTA1, TNC, COL6A3, MYL1, LMNA, 
TAGLN2, TPM1 
2.7E-02 
GO:0006979~response to oxidative 
stress 
8 5.5E-04 EGFR, PTK2B, CLU, GAB1, CA3, PDLIM1, TPM1, PXN 2.9E-02 
GO:0003012~muscle system process 8 6.3E-04 MYL6, ALDOA, ACTA1, MYH1, MYL1, MYH4, GJA1, TPM1 3.2E-02 
GO:0006096~glycolysis 5 7.1E-04 ALDOA, PKM2, ENO3, PGK1, ENO1 3.5E-02 
GO:0051017~actin filament bundle 
formation 
4 7.5E-04 EZR, PTK2B, ACTN1, ABL2 3.5E-02 
GO:0051651~maintenance of location 
in cell 
5 7.7E-04 TLN1, CAV1, EZR, PDIA3, FGFR1OP 3.5E-02 
GO:0045185~maintenance of protein 
location 
5 7.7E-04 TLN1, CAV1, EZR, PDIA3, FGFR1OP 3.5E-02 
GO:0044275~cellular carbohydrate 
catabolic process 
6 8.4E-04 ALDOA, PKM2, ENO3, PGK1, PYGB, ENO1 3.7E-02 
GO:0043549~regulation of kinase 
activity 
11 1.1E-03 EGFR, SPRY1, CAV1, YWHAG, PTK2B, GAB1, SHC1, VAV2, 
THBS1, SPRY4, GAP43 
4.4E-02 
GO:0051592~response to calcium ion 5 1.3E-03 EGFR, ACTG1, CAV1, PTK2B, THBS1 5.2E-02 
GO:0051270~regulation of cell motion 8 1.4E-03 EGFR, LYN, PTK2B, GAB1, ACTN1, THBS1, TPM1, VCL 5.6E-02 
 
Decreased protein expression in GBM39 and 59 due to 2   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0006323~DNA packaging 8 2.1E-06 HIST1H2BB, SET, HIST1H4A, HIST1H2BL, HIST1H1B, 
SMARCA5, H2AFX, SMC4 
0.002 
GO:0006334~nucleosome 
assembly 
7 4.2E-06 HIST1H2BB, SET, HIST1H4A, HIST1H2BL, HIST1H1B, 
SMARCA5, H2AFX 
0.002 
GO:0033554~cellular response to 
stress 
14 4.7E-06 CDK1, HMGB1, MSH6, CRYAB, MAP1B, RPA3, TYMS, MAPK1, 
MAPK12, ALB, GSK3B, PCNA, H2AFX, APEX1 
0.002 
GO:0031497~chromatin 
assembly 
7 5.1E-06 HIST1H2BB, SET, HIST1H4A, HIST1H2BL, HIST1H1B, 
SMARCA5, H2AFX 
0.001 
GO:0065004~protein-DNA 
complex assembly 
7 6.7E-06 HIST1H2BB, SET, HIST1H4A, HIST1H2BL, HIST1H1B, 
SMARCA5, H2AFX 
0.001 
GO:0034728~nucleosome 
organization 
7 7.6E-06 HIST1H2BB, SET, HIST1H4A, HIST1H2BL, HIST1H1B, 
SMARCA5, H2AFX 
0.001 
GO:0006333~chromatin 
assembly or disassembly 
7 4.5E-05 HIST1H2BB, SET, HIST1H4A, HIST1H2BL, HIST1H1B, 
SMARCA5, H2AFX 
0.007 
GO:0006974~response to DNA 
damage stimulus 
10 1.1E-04 CDK1, HMGB1, TYMS, MAPK1, MSH6, MAPK12, PCNA, H2AFX, 
APEX1, RPA3 
0.015 
GO:0007242~intracellular 
signaling cascade 
18 1.4E-04 PRKCA, C9ORF86, CDK1, MSH6, CRYAB, PARK7, TYMS, 
MAPK1, MAPK12, HIST1H4A, GSK3B, ANP32A, PCNA, RHEB, 
GNAS, H2AFX, STMN1, PAG1 
0.017 
GO:0051276~chromosome 
organization 
11 1.6E-04 HMGB1, HIST1H2BB, KDM1A, MSH6, SET, HIST1H4A, 
HIST1H2BL, HIST1H1B, SMARCA5, H2AFX, SMC4 
0.017 
GO:0034621~cellular 
macromolecular complex subunit 
organization 
9 4.5E-04 NUP133, HIST1H2BB, SET, HIST1H4A, HIST1H2BL, HIST1H1B, 
SMARCA5, H2AFX, STMN1 
0.042 
GO:0006325~chromatin 
organization 
9 6.5E-04 HMGB1, HIST1H2BB, KDM1A, SET, HIST1H4A, HIST1H2BL, 
HIST1H1B, SMARCA5, H2AFX 
0.056 
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Table S4. GO classification of the proteins influenced by the unbalanced process 3   
Increased protein expression in GBM15 due to 3   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0030036~actin cytoskeleton 
organization 
10 3.2E-05 ACTG1, TLN1, CNN3, GSN, PTK2B, BCAR1, CFL1, 
FSCN1, FGD5, DBN1 
0.032 
GO:0007173~epidermal growth factor 
receptor signaling pathway 
5 4.3E-05 EGFR, ERBB2IP, PTK2B, BCAR1, SRC 0.022 
GO:0030029~actin filament-based process 10 5.2E-05 ACTG1, TLN1, CNN3, GSN, PTK2B, BCAR1, CFL1, 
FSCN1, FGD5, DBN1 
0.018 
GO:0007010~cytoskeleton organization 13 5.8E-05 TLN1, CNN3, BCAR1, FSCN1, ACTG1, ERBB2IP, PTK2B, 
GSN, FGFR1OP, CFL1, SYNM, FGD5, DBN1 
0.015 
GO:0007265~Ras protein signal 
transduction 
7 1.0E-04 MAPK1, DBNL, NTRK1, MAPK3, CFL1, COL1A2, SRC 0.020 
GO:0010035~response to inorganic 
substance 
9 1.0E-04 EGFR, ACTG1, GSN, PTK2B, FGB, EEF1A2, PRDX5, 
COL1A1, PXN 
0.018 
GO:0006928~cell motion 13 1.3E-04 TLN1, CCDC88A, BCAR1, PODXL, VIM, VAV2, SRC, 
ACTG1, PTK2B, ROBO1, CFL1, HSPB1, GAP43 
0.019 
GO:0007015~actin filament organization 6 1.6E-04 GSN, PTK2B, BCAR1, CFL1, FSCN1, DBN1 0.020 
GO:0030030~cell projection organization 11 2.8E-04 EGFR, PARD3, SEPT2, CCDC88A, S100B, ROBO1, 
PTK2B, UCHL1, FGD5, VAV2, GAP43 
0.031 
 
Decreased protein expression in GBM15 to 3   
There are no statistically significant biological categories. 
 
Table S5. GO classification of the proteins influenced by the unbalanced process 4   
Increased protein expression in GBM59 due to 4   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0006468~protein amino 
acid phosphorylation 
16 9.7E-06 EGFR, CDK1, TAOK1, PMVK, EPHA2, EPHA4, MAPK1, MAPK12, 
MAPK14, NTRK1, DYRK1A, HIPK2, MAPK3, CFL1, YES1, ABL2 
0.010 
GO:0007265~Ras protein 
signal transduction 
7 4.1E-05 MAPK1, MAPK12, MAPK14, NTRK1, MAPK3, CFL1, PARK7 0.020 
GO:0016310~phosphorylation 16 8.0E-05 EGFR, CDK1, TAOK1, PMVK, EPHA2, EPHA4, MAPK1, MAPK12, 
MAPK14, NTRK1, DYRK1A, HIPK2, MAPK3, CFL1, YES1, ABL2 
0.026 
GO:0030029~actin filament-
based process 
9 1.0E-04 EPB41L2, ACTG1, EZR, MYL1, CFL1, MYH4, ACTN1, ABL2, DBN1 0.025 
GO:0006796~phosphate 
metabolic process 
17 2.1E-04 EGFR, CDK1, TAOK1, PMVK, ACP1, EPHA2, EPHA4, MAPK1, 
MAPK12, MAPK14, NTRK1, DYRK1A, HIPK2, MAPK3, CFL1, 
YES1, ABL2 
0.040 
GO:0006793~phosphorus 
metabolic process 
17 2.1E-04 EGFR, CDK1, TAOK1, PMVK, ACP1, EPHA2, EPHA4, MAPK1, 
MAPK12, MAPK14, NTRK1, DYRK1A, HIPK2, MAPK3, CFL1, 
YES1, ABL2 
0.040 
GO:0030182~neuron 
differentiation 
11 3.0E-04 EGFR, EPHA4, TUBB, S100B, CD44, MTPN, NTRK1, UCHL1, 
HPRT1, GAP43, EPHA2 
0.049 
GO:0006006~glucose 
metabolic process 
7 3.3E-04 LDHB, LDHA, CRYAB, MAPK14, PKM2, ENO1, PGM2L1 0.045 
 
Increased protein expression in GBM39 due to 4   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
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GO:0010033~response to organic 
substance 
15 8.62E-05 A2M, LYN, HSPA1A, STAT1, B2M, DDR1, PTK2B, APOE, 
MAPK14, GAB1, COL6A2, PDGFRA, HSPB1, GNAS, THBS1 
0.095433 
GO:0018108~peptidyl-tyrosine 
phosphorylation 
5 0.000161 DDR1, LYN, PTK2B, PDGFRA, STAT1 0.089328 
GO:0006916~anti-apoptosis 8 0.00023 CDK1, TMX1, APOE, ANXA1, HSPB1, HSPA1A, HSPA5, THBS1 0.052103 
GO:0042981~regulation of 
apoptosis 
15 0.00027 TMX1, CDK1, ARHGEF6, TUBB2C, ANXA1, HSPA1A, VAV2, 
STAT1, YWHAE, ALB, APOE, HSPB1, HSPA5, MX1, THBS1 
0.050988 
GO:0043067~regulation of 
programmed cell death 
15 0.000299 TMX1, CDK1, ARHGEF6, TUBB2C, ANXA1, HSPA1A, VAV2, 
STAT1, YWHAE, ALB, APOE, HSPB1, HSPA5, MX1, THBS1 
0.048432 
GO:0010941~regulation of cell 
death 
15 0.00031 TMX1, CDK1, ARHGEF6, TUBB2C, ANXA1, HSPA1A, VAV2, 
STAT1, YWHAE, ALB, APOE, HSPB1, HSPA5, MX1, THBS1 
0.044103 
GO:0006928~cell motion 11 0.000521 PTK2B, MAPK14, TUBB2C, TXN, ANXA1, HSPB1, VAV2, 
TOP2B, THBS1, YWHAE, FN1 
0.06519 
GO:0006091~generation of 
precursor metabolites and energy 
9 0.000558 TMX1, NDUFA5, SLC1A3, NDUFV1, NDUFS8, TXN, IDH2, 
GNAS, GAPDH 
0.062865 
GO:0022900~electron transport 
chain 
6 0.000599 TMX1, NDUFA5, SLC1A3, NDUFV1, NDUFS8, TXN 0.06143 
 
 
Table S6. GO classification of the proteins influenced by the unbalanced process 5    
Increased protein expression in GBM6 due to 5   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0006091~generation of 
precursor metabolites and energy 
17 8.6E-11 ATP5D, ALDOA, LDHB, NDUFA5, ATP5B, ALDOC, SLC1A3, 
GSK3B, IDH2, ATP5L, ATP5A1, GAPDH, ETFB, MDH2, 
ACAA1, ENO1, ETFA 
0.000 
GO:0007265~Ras protein signal 
transduction 
8 4.2E-06 MAPK1, MAPK12, MAPK14, MAPK3, CFL1, COL1A2, SDCBP, 
PARK7 
0.002 
GO:0006006~glucose metabolic 
process 
9 5.1E-06 ALDOA, LDHB, CRYAB, MAPK14, GSK3B, ALDOC, GAPDH, 
MDH2, ENO1 
0.002 
GO:0055114~oxidation reduction 16 9.1E-06 ALDH6A1, LDHB, NDUFA5, ACADM, PIPOX, CBR1, SLC1A3, 
HSDL2, PRDX6, AKR1B1, AKR7A2, IDH2, GAPDH, ETFB, 
MDH2, ETFA 
0.003 
GO:0006096~glycolysis 6 1.1E-05 ALDOA, LDHB, ALDOC, GAPDH, MDH2, ENO1 0.002 
GO:0046164~alcohol catabolic 
process 
7 1.1E-05 ALDOA, LDHB, ALDOC, COMT, GAPDH, MDH2, ENO1 0.002 
GO:0006754~ATP biosynthetic 
process 
7 2.0E-05 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.003 
GO:0019318~hexose metabolic 
process 
9 2.7E-05 ALDOA, LDHB, CRYAB, MAPK14, GSK3B, ALDOC, GAPDH, 
MDH2, ENO1 
0.004 
GO:0006793~phosphorus metabolic 
process 
19 2.7E-05 PRKCA, ATP5D, FYB, CDK1, PPP6C, NDUFA5, INPPL1, 
PTPRZ1, ATP5B, HCK, MAPK1, MAPK12, MAPK14, GSK3B, 
DYRK1A, MAPK3, CFL1, ATP5L, ATP5A1 
0.003 
GO:0006796~phosphate metabolic 
process 
19 2.7E-05 PRKCA, ATP5D, FYB, CDK1, PPP6C, NDUFA5, INPPL1, 
PTPRZ1, ATP5B, HCK, MAPK1, MAPK12, MAPK14, GSK3B, 
DYRK1A, MAPK3, CFL1, ATP5L, ATP5A1 
0.003 
GO:0006007~glucose catabolic 
process 
6 3.1E-05 ALDOA, LDHB, ALDOC, GAPDH, MDH2, ENO1 0.003 
GO:0009206~purine ribonucleoside 
triphosphate biosynthetic process 
7 3.4E-05 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.003 
GO:0009145~purine nucleoside 
triphosphate biosynthetic process 
7 3.6E-05 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.003 
GO:0009201~ribonucleoside 
triphosphate biosynthetic process 
7 3.6E-05 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.003 
GO:0015992~proton transport 6 3.9E-05 ATP5D, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.003 
GO:0009142~nucleoside 
triphosphate biosynthetic process 
7 4.3E-05 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.003 
GO:0010035~response to inorganic 
substance 
9 4.3E-05 PRKCA, ATP5D, SLC1A3, GATM, PRDX6, CRYAB, RELA, 
PARK7, MT3 
0.003 
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GO:0006818~hydrogen transport 6 4.6E-05 ATP5D, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.003 
GO:0046034~ATP metabolic 
process 
7 5.0E-05 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.003 
GO:0019320~hexose catabolic 
process 
6 7.1E-05 ALDOA, LDHB, ALDOC, GAPDH, MDH2, ENO1 0.004 
GO:0005996~monosaccharide 
metabolic process 
9 7.5E-05 ALDOA, LDHB, CRYAB, MAPK14, GSK3B, ALDOC, GAPDH, 
MDH2, ENO1 
0.004 
GO:0046365~monosaccharide 
catabolic process 
6 8.2E-05 ALDOA, LDHB, ALDOC, GAPDH, MDH2, ENO1 0.004 
GO:0009152~purine ribonucleotide 
biosynthetic process 
7 9.2E-05 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.005 
GO:0009205~purine ribonucleoside 
triphosphate metabolic process 
7 9.2E-05 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.005 
GO:0009199~ribonucleoside 
triphosphate metabolic process 
7 9.7E-05 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.005 
GO:0000302~response to reactive 
oxygen species 
6 1.1E-04 PRKCA, PRDX6, CRYAB, RELA, PARK7, MT3 0.005 
GO:0009144~purine nucleoside 
triphosphate metabolic process 
7 1.2E-04 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.005 
GO:0016310~phosphorylation 16 1.2E-04 PRKCA, FYB, ATP5D, CDK1, NDUFA5, ATP5B, HCK, MAPK1, 
MAPK12, GSK3B, MAPK14, DYRK1A, MAPK3, CFL1, ATP5L, 
ATP5A1 
0.005 
GO:0007264~small GTPase 
mediated signal transduction 
10 1.2E-04 GDI1, MAPK1, MAPK12, MAPK14, MAPK3, CFL1, COL1A2, 
SDCBP, VAV2, PARK7 
0.005 
GO:0009260~ribonucleotide 
biosynthetic process 
7 1.3E-04 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.005 
GO:0009141~nucleoside 
triphosphate metabolic process 
7 1.7E-04 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.007 
GO:0044275~cellular carbohydrate 
catabolic process 
6 0.000192 ALDOA, LDHB, ALDOC, GAPDH, MDH2, ENO1 0.007 
GO:0044271~nitrogen compound 
biosynthetic process 
10 0.000198 ATP5D, ALDOA, GLUL, ATP5J2, SLC1A3, ATP5B, ATP5L, 
ATP1A2, ATP5A1, APRT 
0.007 
GO:0034404~nucleobase, 
nucleoside and nucleotide 
biosynthetic process 
8 0.000208 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1, 
APRT 
0.007 
GO:0034654~nucleobase, 
nucleoside, nucleotide and nucleic 
acid biosynthetic process 
8 0.000208 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1, 
APRT 
0.007 
GO:0009150~purine ribonucleotide 
metabolic process 
7 0.000228 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.008 
GO:0034220~ion transmembrane 
transport 
5 0.000248 ATP5D, ATP5B, ATP5L, ATP1A2, ATP5A1 0.008 
GO:0006916~anti-apoptosis 8 0.00031 CDK1, PEA15, CRYAB, RELA, GSK3B, CFL1, ANXA1, HSPB1 0.010 
GO:0009259~ribonucleotide 
metabolic process 
7 0.000321 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.010 
GO:0006164~purine nucleotide 
biosynthetic process 
7 0.000333 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.010 
GO:0009188~ribonucleoside 
diphosphate biosynthetic process 
3 0.000385 ATP5D, ATP5B, ATP5A1 0.011 
GO:0006172~ADP biosynthetic 
process 
3 0.000385 ATP5D, ATP5B, ATP5A1 0.011 
GO:0009136~purine nucleoside 
diphosphate biosynthetic process 
3 0.000385 ATP5D, ATP5B, ATP5A1 0.011 
GO:0009180~purine ribonucleoside 
diphosphate biosynthetic process 
3 0.000385 ATP5D, ATP5B, ATP5A1 0.011 
GO:0006979~response to oxidative 
stress 
7 0.000575 PRKCA, GATM, PRDX6, CRYAB, RELA, PARK7, MT3 0.016 
GO:0046031~ADP metabolic 
process 
3 0.000576 ATP5D, ATP5B, ATP5A1 0.016 
GO:0016052~carbohydrate catabolic 
process 
6 0.000609 ALDOA, LDHB, ALDOC, GAPDH, MDH2, ENO1 0.017 
GO:0006575~cellular amino acid 
derivative metabolic process 
7 0.000613 SLC1A3, CKM, ACADM, GATM, GSTK1, DHPS, COMT 0.016 
GO:0009133~nucleoside 
diphosphate biosynthetic process 
3 0.000803 ATP5D, ATP5B, ATP5A1 0.021 
GO:0009135~purine nucleoside 
diphosphate metabolic process 
3 0.001066 ATP5D, ATP5B, ATP5A1 0.027 
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GO:0009179~purine ribonucleoside 
diphosphate metabolic process 
3 0.001066 ATP5D, ATP5B, ATP5A1 0.027 
GO:0009165~nucleotide 
biosynthetic process 
7 0.001109 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.027 
GO:0006163~purine nucleotide 
metabolic process 
7 0.001109 ATP5D, ALDOA, ATP5J2, ATP5B, ATP5L, ATP1A2, ATP5A1 0.027 
GO:0042981~regulation of apoptosis 14 0.001451 PRKCA, BID, CDK1, CRYAB, RELA, ANXA1, VAV2, YWHAE, 
MIF, PEA15, MAPK1, GSK3B, CFL1, HSPB1 
0.035 
GO:0019226~transmission of nerve 
impulse 
9 0.001577 PRKCA, MAPK1, SLC1A3, SDCBP, QKI, ATP1A2, COMT, 
NCAN, PARK7 
0.037 
GO:0043067~regulation of 
programmed cell death 
14 0.001586 PRKCA, BID, CDK1, CRYAB, RELA, ANXA1, VAV2, YWHAE, 
MIF, PEA15, MAPK1, GSK3B, CFL1, HSPB1 
0.036 
GO:0010941~regulation of cell 
death 
14 0.001639 PRKCA, BID, CDK1, CRYAB, RELA, ANXA1, VAV2, YWHAE, 
MIF, PEA15, MAPK1, GSK3B, CFL1, HSPB1 
0.037 
GO:0043066~negative regulation of 
apoptosis 
9 0.001694 CDK1, PEA15, CRYAB, RELA, GSK3B, CFL1, ANXA1, HSPB1, 
MIF 
0.037 
GO:0001504~neurotransmitter 
uptake 
3 0.001699 SLC1A3, ATP1A2, PARK7 0.037 
GO:0009185~ribonucleoside 
diphosphate metabolic process 
3 0.001699 ATP5D, ATP5B, ATP5A1 0.037 
GO:0043069~negative regulation of 
programmed cell death 
9 0.00185 CDK1, PEA15, CRYAB, RELA, GSK3B, CFL1, ANXA1, HSPB1, 
MIF 
0.039 
GO:0060548~negative regulation of 
cell death 
9 0.001882 CDK1, PEA15, CRYAB, RELA, GSK3B, CFL1, ANXA1, HSPB1, 
MIF 
0.039 
GO:0015986~ATP synthesis 
coupled proton transport 
4 0.002 ATP5D, ATP5B, ATP5L, ATP5A1 0.041 
GO:0015985~energy coupled proton 
transport, down electrochemical 
gradient 
4 0.002 ATP5D, ATP5B, ATP5L, ATP5A1 0.041 
  
 Decreased protein expression in GBM6 due to 5   
 
 
Table S7. GO classification of the proteins influenced by the unbalanced process 6    
Increased protein expression in GBM26 due to 6   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0030036~actin cytoskeleton 
organization 
12 6.94E-07 ACTG1, ALDOA, TLN1, PTK2B, BCAR1, CFL1, SDCBP, 
TMSB4X, FGD5, WAS, ITGB1, LLGL1 
0.000774 
GO:0006468~protein amino acid 
phosphorylation 
19 1.19E-06 EGFR, FYB, DBNL, CDK1, LYN, TAOK1, PTPRA, TFG, 
FER, EPHA2, SPAG9, PTK2B, DYRK1A, CFL1, MAPK3, 
PDGFRA, SHC1, MERTK, YES1 
0.000665 
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0007169~transmembrane 
receptor protein tyrosine 
kinase signaling pathway 
10 5.4E-06 EGFR, DDR1, EPHA4, MPZL1, ERBB2IP, NTRK1, BCAR1, PDGFRA, 
ABI1, EPHA2 
0.005 
GO:0007167~enzyme linked 
receptor protein signaling 
pathway 
10 1.5E-04 EGFR, DDR1, EPHA4, MPZL1, ERBB2IP, NTRK1, BCAR1, PDGFRA, 
ABI1, EPHA2 
0.045 
GO:0018212~peptidyl-
tyrosine modification 
5 1.6E-04 TYK2, DDR1, PDGFRA, ABI1, FER 0.038 
GO:0007010~cytoskeleton 
organization 
11 1.9E-04 EPB41L2, ERBB2IP, CNN3, TLN2, BCAR1, MAP2, MAP1B, SDCBP, 
ACTN1, ITGB1, DBN1 
0.035 
GO:0030030~cell projection 
organization 
10 2.6E-04 EGFR, ACTB, EPHA4, PARD3, MAP2K1, MAP2, CLU, CAPG, MAP1B, 
SDCBP 
0.039 
GO:0032989~cellular 
component morphogenesis 
10 4.5E-04 EGFR, S100A4, ACTB, EPHA4, PARD3, MAP2K1, ERBB2IP, CLU, 
MAP1B, ITGB1 
0.058 
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GO:0030029~actin filament-based 
process 
12 1.31E-06 ACTG1, ALDOA, TLN1, PTK2B, BCAR1, CFL1, SDCBP, 
TMSB4X, FGD5, WAS, ITGB1, LLGL1 
0.000486 
GO:0007010~cytoskeleton 
organization 
15 2.92E-06 ALDOA, TLN1, TLN2, BCAR1, MAP1B, DOCK7, WAS, 
ITGB1, LLGL1, ACTG1, PTK2B, CFL1, SDCBP, TMSB4X, 
FGD5 
0.000813 
GO:0016310~phosphorylation 20 3.84E-06 EGFR, FYB, DBNL, CDK1, LYN, TAOK1, PTPRA, TFG, 
FER, EPHA2, SPAG9, PTK2B, DYRK1A, CFL1, MAPK3, 
PDGFRA, SHC1, MERTK, YES1, ATP5I 
0.000856 
GO:0006796~phosphate metabolic 
process 
22 4.91E-06 EGFR, FYB, DBNL, CDK1, LYN, TAOK1, PTPRA, TFG, 
FER, EPHA2, GPD1L, SPAG9, PTK2B, DYRK1A, CFL1, 
MAPK3, PDGFRA, SHC1, INPP5D, MERTK, YES1, ATP5I 
0.000913 
GO:0006793~phosphorus metabolic 
process 
22 4.91E-06 EGFR, FYB, DBNL, CDK1, LYN, TAOK1, PTPRA, TFG, 
FER, EPHA2, GPD1L, SPAG9, PTK2B, DYRK1A, CFL1, 
MAPK3, PDGFRA, SHC1, INPP5D, MERTK, YES1, ATP5I 
0.000913 
GO:0032989~cellular component 
morphogenesis 
13 2.88E-05 S100A4, EGFR, S100A6, MAP1B, GJA1, DOCK7, ITGB1, 
LLGL1, ACTG1, SLC1A3, ROBO1, CFL1, SLITRK5 
0.004574 
GO:0034329~cell junction assembly 5 0.000214 TLN1, TLN2, PTK2B, GJA1, VCL 0.029322 
GO:0000902~cell morphogenesis 11 0.000252 EGFR, S100A4, S100A6, SLC1A3, ROBO1, CFL1, MAP1B, 
GJA1, DOCK7, SLITRK5, LLGL1 
0.0307 
GO:0007043~cell-cell junction 
assembly 
4 0.000278 TLN1, TLN2, GJA1, VCL 0.030524 
GO:0030030~cell projection 
organization 
11 0.000328 EGFR, S100A6, ROBO1, PTK2B, MAP1B, SDCBP, GJA1, 
DOCK7, FGD5, SLITRK5, VCL 
0.032685 
GO:0018108~peptidyl-tyrosine 
phosphorylation 
5 0.000335 LYN, PTK2B, DYRK1A, PDGFRA, FER 0.030621 
GO:0018212~peptidyl-tyrosine 
modification 
5 0.000395 LYN, PTK2B, DYRK1A, PDGFRA, FER 0.033288 
GO:0051272~positive regulation of 
cell motion 
6 0.000718 EGFR, SPAG9, LYN, PTK2B, BCAR1, PDGFRA 0.055613 
GO:0034330~cell junction 
organization 
5 0.000762 TLN1, TLN2, PTK2B, GJA1, VCL 0.055107 
 
Decreased protein expression in GBM26 due to 6   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0034728~nucleosome 
organization 
8 4.19E-06 H1F0, HIST1H2BB, HIST2H2AA3, HIST1H4A, HIST1H1B, 
H2AFY, H2AFX, HMGA1 
0.004635 
GO:0006323~DNA packaging 8 1.91E-05 H1F0, HIST1H2BB, HIST2H2AA3, HIST1H4A, HIST1H1B, 
H2AFY, H2AFX, SMC4 
0.010536 
GO:0006334~nucleosome assembly 7 2.84E-05 H1F0, HIST1H2BB, HIST2H2AA3, HIST1H4A, HIST1H1B, 
H2AFY, H2AFX 
0.01045 
GO:0006333~chromatin assembly or 
disassembly 
8 3.25E-05 H1F0, HIST1H2BB, HIST2H2AA3, HIST1H4A, HIST1H1B, 
H2AFY, H2AFX, HMGA1 
0.008968 
GO:0031497~chromatin assembly 7 3.47E-05 H1F0, HIST1H2BB, HIST2H2AA3, HIST1H4A, HIST1H1B, 
H2AFY, H2AFX 
0.007668 
GO:0065004~protein-DNA complex 
assembly 
7 4.47E-05 H1F0, HIST1H2BB, HIST2H2AA3, HIST1H4A, HIST1H1B, 
H2AFY, H2AFX 
0.008243 
 
Table S8. GO classification of the proteins influenced by the unbalanced process 7    
Increased protein expression in GBM6 due to 7   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0007173~epidermal growth 
factor receptor signaling pathway 
7 2.45E-08 EGFR, EPS15, ERBB2IP, PTK2B, BCAR1, GAB1, SHC1 2.75E-05 
GO:0007169~transmembrane 
receptor protein tyrosine kinase 
signaling pathway 
12 2.65E-07 EGFR, EPS15, DDR1, EPHA4, MPZL1, ERBB2IP, PTK2B, 
BCAR1, GAB1, PDGFRA, ABI1, SHC1 
0.000149 
GO:0030029~actin filament-based 
process 
12 5.5E-07 EPB41L2, ALDOA, ACTA1, CNN3, PTK2B, BCAR1, MYL1, 
MYH4, ACTN1, ARF6, FGD5, ITGB1 
0.000206 
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GO:0007167~enzyme linked receptor 
protein signaling pathway 
13 2.62E-06 EGFR, MPZL1, BCAR1, ABI1, EPS15, EPHA4, DDR1, 
ERBB2IP, PTK2B, ZFYVE16, GAB1, PDGFRA, SHC1 
0.000735 
GO:0030036~actin cytoskeleton 
organization 
10 1.89E-05 EPB41L2, ALDOA, ACTA1, CNN3, PTK2B, BCAR1, ACTN1, 
ARF6, FGD5, ITGB1 
0.004227 
GO:0006796~phosphate metabolic 
process 
19 6.09E-05 EGFR, NDUFA4, CDK1, INPPL1, ABI1, TIMM50, PPA1, 
GPD1L, TYK2, DDR1, EPHA4, PTK2B, UQCRH, GAB1, 
PDGFRA, STK39, SHC1, MERTK, YES1 
0.01132 
GO:0006793~phosphorus metabolic 
process 
19 6.09E-05 EGFR, NDUFA4, CDK1, INPPL1, ABI1, TIMM50, PPA1, 
GPD1L, TYK2, DDR1, EPHA4, PTK2B, UQCRH, GAB1, 
PDGFRA, STK39, SHC1, MERTK, YES1 
0.01132 
GO:0018108~peptidyl-tyrosine 
phosphorylation 
5 0.000241 TYK2, DDR1, PTK2B, PDGFRA, ABI1 0.037967 
GO:0018212~peptidyl-tyrosine 
modification 
5 0.000285 TYK2, DDR1, PTK2B, PDGFRA, ABI1 0.03919 
GO:0010035~response to inorganic 
substance 
8 0.000427 EGFR, BSG, SLC1A3, PTK2B, PDGFRA, PRDX3, PARK7, MT3 0.051902 
 
Decreased protein expression in GBM6 due to 7   
GO Term Count EASE 
score 
Proteins Benjamini 
correction 
GO:0065003~macromolecular 
complex assembly 
21 1.85E-07 CUTA, H1F0, HIST2H2AA3, PARD3, HIST1H1B, HP1BP3, GJA1, 
WAS, LLGL1, TUBB, NDUFS4, HIST1H4A, APOE, NDUFS8, 
SMARCA5, TUBB6, H2AFY, H2AFX, SEPT7, TUBB3, SEPT9 
0.000238 
GO:0043933~macromolecular 
complex subunit organization 
21 5.26E-07 CUTA, H1F0, HIST2H2AA3, PARD3, HIST1H1B, HP1BP3, GJA1, 
WAS, LLGL1, TUBB, NDUFS4, HIST1H4A, APOE, NDUFS8, 
SMARCA5, TUBB6, H2AFY, H2AFX, SEPT7, TUBB3, SEPT9 
0.000339 
GO:0034622~cellular 
macromolecular complex 
assembly 
14 1.17E-06 H1F0, HIST2H2AA3, HIST1H1B, HP1BP3, WAS, TUBB, NDUFS4, 
HIST1H4A, NDUFS8, SMARCA5, TUBB6, H2AFY, H2AFX, TUBB3 
0.000503 
GO:0006323~DNA 
packaging 
9 3.66E-06 H1F0, HIST2H2AA3, HIST1H4A, HP1BP3, HIST1H1B, SMARCA5, 
H2AFY, H2AFX, SMC4 
0.00118 
GO:0006334~nucleosome 
assembly 
8 4.1E-06 H1F0, HIST2H2AA3, HIST1H4A, HP1BP3, HIST1H1B, SMARCA5, 
H2AFY, H2AFX 
0.001056 
GO:0034621~cellular 
macromolecular complex 
subunit organization 
14 4.21E-06 H1F0, HIST2H2AA3, HIST1H1B, HP1BP3, WAS, TUBB, NDUFS4, 
HIST1H4A, NDUFS8, SMARCA5, TUBB6, H2AFY, H2AFX, TUBB3 
0.000903 
GO:0031497~chromatin 
assembly 
8 5.19E-06 H1F0, HIST2H2AA3, HIST1H4A, HP1BP3, HIST1H1B, SMARCA5, 
H2AFY, H2AFX 
0.000955 
GO:0065004~protein-DNA 
complex assembly 
8 7.01E-06 H1F0, HIST2H2AA3, HIST1H4A, HP1BP3, HIST1H1B, SMARCA5, 
H2AFY, H2AFX 
0.001128 
GO:0034728~nucleosome 
organization 
8 8.09E-06 H1F0, HIST2H2AA3, HIST1H4A, HP1BP3, HIST1H1B, SMARCA5, 
H2AFY, H2AFX 
0.001159 
GO:0006333~chromatin 
assembly or disassembly 
8 6.14E-05 H1F0, HIST2H2AA3, HIST1H4A, HP1BP3, HIST1H1B, SMARCA5, 
H2AFY, H2AFX 
0.007887 
GO:0030198~extracellular 
matrix organization 
7 0.000164 LUM, HSD17B12, COL1A2, COL12A1, POSTN, NID1, ANXA2 0.018991 
GO:0008104~protein 
localization 
18 0.000476 EGFR, CUTA, FYB, RAB3GAP2, TLN1, PDIA3, LYN, TLN2, VTA1, 
AKAP12, ITGA2, CLTC, YWHAE, AP3M1, GSK3B, FGFR1OP, 
SDCBP, SRP9 
0.049879 
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3. PCA analysis 
Using as an input a matrix that included entire dataset (phosphorylated and unmodified proteins) we performed 
standard PCA analysis 10. PCA analysis is a statistical approach that concentrates on variations relative to the 
mean. Rows of the input matrix correspond to 8 GBM tumors (observations), columns to the the mean-centered 
measured proteins (variables).  At the end of the analysis we receive clusters of the proteins with similar behavior 
relatively to the mean. We show that only proteins with highest variance are resolved well.   
The results of the PCA analysis yields a big 1766-by-1766 matrix, in which each column contains coefficients (or 
contributions of the examined proteins) for one principal component (PC). The analysis of the mean-centered data 
of 8 different GBM tumors can mathematically yield maximum of 7 non-zero principle components. Fig. S7a, b 
and c illustrates the representation of the measured protein data in the principal component space and shows 
sorted values of the protein coefficients for the PC1 (Fig.S7d). We used Matlab to calculate how many 
components account for 92% or 98% of the variance among the GBM tumors. Four first Principal components 
(PC) accounted for 92% of the data variance and 6 out of 7 PCs account for 98% of the variance. All the proteins 
with the coefficients more than 0.01 or less than -0.01 (Fig.S7d, proteins with the coefficients that exceed 
positively or negatively the zero red box in the plot) were examined further for fitting into the identified PC scores 
(Fig.S7) in order to eliminate noise. Only the proteins that change their expression levels according to the 
identified PC scores were included further in the classification according to the GO biological categories using 
DAVID database 5. Proteins with noisy behaviors were excluded from the lists. For example proteins contributing 
significantly to the PC1 should show the same behavior in the GBM 10 and 12 (eg. increase in those tumors 
relatively to the average protein expression) but have an opposite behavior in the GBM39 (as shown in the PC1 
score in Fig.S7a).  
Biological categories were considered as statistically significant enriched groups if they had EASE score and 
Benjamini correction values  0.05. Tables including these categories are presented below (Tables S9–S13). 
Mainly phospho-proteins contribute to all PCs (Additional Table SI). Additional Table SI includes lists of all 
significant proteins contributing either to the constraints identified by Surprisal analysis or to the PCs identified 
by the PCA algorithm.  
To decrease the effect of the variables with the highest variance that may dominate first principal components we 
used correlation matrix instead of covariance matrix to standardize the data. This method yielded plots without a 
flat region representing zero values, thereby not allowing identification of the significantly contributing proteins 
to the different PCs (Fig.S8). 
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Classification of the proteins contributing to the PCs according to the GO biological categories. 
A more complete list of proteins that contribute significantly to the different constraints is provided in the 
Additional Table SI. Tables S9-S13 include both proteins with altered expression and altered phosphorylation. 
To distinguish between proteins with altered expression and altered phosphorylation in every constraint see 
Additional Table SI. Almost all the proteins contributing significantly to the principle components are 
phosphoproteins.  
Principal component 1(PC1,GBM10 vs GBM39) 
No significant biological categories were identified besides one GO category named”phosphorylation”. 
Table S9. GO protein classification of the proteins contributing to the PC2 ( GBM15 vs GBM6) 
Increased protein expression in GBM15 
GO Term Count pValue proteins Benjamini 
correction 
GO:0006468~protein amino acid 
phosphorylation 
10 4.84E-06 EGFR, EPHA4, MAPK1, PRPF4B, GSK3B, HIPK2, 
MAPK3, MAP2, PTPRA, YES1 
0.00273 
GO:0006796~phosphate metabolic 
process 
11 1.4E-05 EGFR, EPHA4, MAPK1, PRPF4B, PTPRZ1, GSK3B, 
HIPK2, MAPK3, MAP2, PTPRA, YES1 
0.003957 
GO:0006793~phosphorus metabolic 
process 
11 1.4E-05 EGFR, EPHA4, MAPK1, PRPF4B, PTPRZ1, GSK3B, 
HIPK2, MAPK3, MAP2, PTPRA, YES1 
0.003957 
GO:0016310~phosphorylation 10 2.11E-05 EGFR, EPHA4, MAPK1, PRPF4B, GSK3B, HIPK2, 
MAPK3, MAP2, PTPRA, YES1 
0.003957 
GO:0007010~cytoskeleton 
organization 
7 0.000223 EPB41L2, ACTG1, TUBB, CNN3, MAP2, ITGB1, DBN1 0.031026 
 
Table S10. GO protein classification of the proteins contributing to the PC3 (GBM6 vs GBM39,59). 
Increased protein expression in 6 
GO Term Count pValue proteins Benjamini 
correction 
GO:0006793~phosphorus metabolic 
process 
9 2.66E-07 MAPK1, PRPF4B, MAPK12, PTPRZ1, MAPK14, GSK3B, 
HIPK2, DYRK1A, MAPK3 
9.32E-05 
GO:0006796~phosphate metabolic 
process 
9 2.66E-07 MAPK1, PRPF4B, MAPK12, PTPRZ1, MAPK14, GSK3B, 
HIPK2, DYRK1A, MAPK3 
9.32E-05 
GO:0006468~protein amino acid 
phosphorylation 
8 4.38E-07 MAPK1, PRPF4B, MAPK12, MAPK14, GSK3B, HIPK2, 
DYRK1A, MAPK3 
7.68E-05 
GO:0016310~phosphorylation 8 1.5E-06 MAPK1, PRPF4B, MAPK12, MAPK14, GSK3B, HIPK2, 
DYRK1A, MAPK3 
0.000176 
GO:0033554~cellular response to stress 6 7.81E-05 MAPK1, MAPK12, MAPK14, GSK3B, HIPK2, MT3 0.00683 
GO:0007265~Ras protein signal 
transduction 
4 9.5E-05 MAPK1, MAPK12, MAPK14, MAPK3 0.006647 
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Table S11. GO protein classification of the proteins contributing to the PC4 (GBM8 vs GBM15) 
Increased protein expression in 15 
GO Term Count pValue proteins Benjamini 
correction 
GO:0018108~peptidyl-tyrosine 
phosphorylation 
10 1.26E-13 TYK2, DDR1, LYN, PTK2B, PDGFRA, ABI2, ABI1, FER, 
ABL2, SRC 
1.13E-10 
GO:0018212~peptidyl-tyrosine 
modification 
10 1.9E-13 TYK2, DDR1, LYN, PTK2B, PDGFRA, ABI2, ABI1, FER, 
ABL2, SRC 
8.55E-11 
GO:0006468~protein amino acid 
phosphorylation 
20 4.11E-12 EGFR, DBNL, LYN, PTPRA, ABI2, ABI1, FER, SRC, TYK2, 
DDR1, EPHA4, PTK2B, MAPK14, GSK3B, HIPK2, MAPK3, 
GAB1, PDGFRA, YES1, ABL2 
1.23E-09 
GO:0016310~phosphorylation 20 9.63E-11 EGFR, DBNL, LYN, PTPRA, ABI2, ABI1, FER, SRC, TYK2, 
DDR1, EPHA4, PTK2B, MAPK14, GSK3B, HIPK2, MAPK3, 
GAB1, PDGFRA, YES1, ABL2 
2.17E-08 
GO:0007167~enzyme linked 
receptor protein signaling pathway 
14 5.98E-10 EGFR, MPZL1, BCAR1, PTPRA, ABI1, SRC, DDR1, 
EPHA4, ERBB2IP, PTK2B, ZFYVE16, GAB1, HIPK2, 
PDGFRA 
1.07E-07 
GO:0007169~transmembrane 
receptor protein tyrosine kinase 
signaling pathway 
12 1.03E-09 EGFR, DDR1, EPHA4, MPZL1, ERBB2IP, PTK2B, BCAR1, 
GAB1, PTPRA, PDGFRA, ABI1, SRC 
1.54E-07 
GO:0030036~actin cytoskeleton 
organization 
12 1.13E-09 EPB41L2, ACTG1, TLN1, CNN3, PTK2B, BCAR1, ABI2, 
FGD5, ABL2, WAS, ITGB1, DBN1 
1.45E-07 
GO:0030029~actin filament-based 
process 
12 2.23E-09 EPB41L2, ACTG1, TLN1, CNN3, PTK2B, BCAR1, ABI2, 
FGD5, ABL2, WAS, ITGB1, DBN1 
2.5E-07 
GO:0006793~phosphorus metabolic 
process 
20 2.63E-09 EGFR, DBNL, LYN, PTPRA, ABI2, ABI1, FER, SRC, TYK2, 
DDR1, EPHA4, PTK2B, MAPK14, GSK3B, HIPK2, MAPK3, 
GAB1, PDGFRA, YES1, ABL2 
2.63E-07 
GO:0006796~phosphate metabolic 
process 
20 2.63E-09 EGFR, DBNL, LYN, PTPRA, ABI2, ABI1, FER, SRC, TYK2, 
DDR1, EPHA4, PTK2B, MAPK14, GSK3B, HIPK2, MAPK3, 
GAB1, PDGFRA, YES1, ABL2 
2.63E-07 
GO:0007010~cytoskeleton 
organization 
14 1.13E-08 TLN1, CAV1, CNN3, BCAR1, ABI2, WAS, ITGB1, ACTG1, 
EPB41L2, ERBB2IP, PTK2B, FGD5, DBN1, ABL2 
1.01E-06 
GO:0007173~epidermal growth 
factor receptor signaling pathway 
6 7.68E-08 EGFR, ERBB2IP, PTK2B, BCAR1, GAB1, SRC 6.28E-06 
GO:0006928~cell motion 12 2.17E-06 ACTG1, EPHA4, TLN1, ROBO1, PTK2B, MAPK14, BCAR1, 
VIM, ABI2, ITGB1, SRC, VCL 
0.000163 
GO:0007015~actin filament 
organization 
6 9.58E-06 PTK2B, BCAR1, ABI2, ABL2, WAS, DBN1 0.000662 
GO:0007155~cell adhesion 13 1.55E-05 EGFR, RPSA, BCAR1, CTNND2, FER, ITGB1, SRC, VCL, 
DDR1, ERBB2IP, PTK2B, ROBO1, ABL2 
0.000993 
GO:0022610~biological adhesion 13 1.57E-05 EGFR, RPSA, BCAR1, CTNND2, FER, ITGB1, SRC, VCL, 
DDR1, ERBB2IP, PTK2B, ROBO1, ABL2 
0.00094 
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GO:0051270~regulation of cell 
motion 
7 0.000114 EGFR, LYN, PTK2B, BCAR1, GAB1, PDGFRA, VCL 0.006387 
GO:0070302~regulation of stress-
activated protein kinase signaling 
pathway 
5 0.000162 DBNL, LYN, PTK2B, HIPK2, GAB1 0.008517 
GO:0010033~response to organic 
substance 
11 0.000492 EGFR, DDR1, CAV1, LYN, PTK2B, MAPK14, BCAR1, 
GAB1, PTPRA, PDGFRA, SRC 
0.024288 
GO:0030334~regulation of cell 
migration 
6 0.000553 EGFR, PTK2B, BCAR1, GAB1, PDGFRA, VCL 0.025836 
GO:0009725~response to hormone 
stimulus 
8 0.000603 CAV1, LYN, PTK2B, BCAR1, GAB1, PTPRA, PDGFRA, 
SRC 
0.026764 
GO:0030030~cell projection 
organization 
8 0.000613 EGFR, EPHA4, SEPT2, ROBO1, PTK2B, ABI2, FGD5, VCL 0.025915 
GO:0001932~regulation of protein 
amino acid phosphorylation 
6 0.000615 EGFR, DBNL, CAV1, LYN, PTK2B, GAB1 0.02483 
GO:0007166~cell surface receptor 
linked signal transduction 
18 0.000617 EGFR, MPZL1, LYN, BCAR1, PTPRA, ABI1, ITGB1, SRC, 
DDR1, EPHA4, ERBB2IP, PTK2B, MAPK14, ZFYVE16, 
GSK3B, HIPK2, GAB1, PDGFRA 
0.023825 
GO:0051272~positive regulation of 
cell motion 
5 0.00062 EGFR, LYN, PTK2B, BCAR1, PDGFRA 0.022981 
GO:0007243~protein kinase cascade 8 0.000633 EGFR, TYK2, DBNL, CAV1, PTK2B, MAPK14, GAB1, SRC 0.022519 
GO:0080135~regulation of cellular 
response to stress 
5 0.000748 DBNL, LYN, PTK2B, HIPK2, GAB1 0.025553 
GO:0043408~regulation of 
MAPKKK cascade 
5 0.000925 DBNL, CAV1, PTK2B, HIPK2, GAB1 0.030349 
GO:0040012~regulation of 
locomotion 
6 0.000984 EGFR, PTK2B, BCAR1, GAB1, PDGFRA, VCL 0.03111 
GO:0007242~intracellular signaling 
cascade 
14 0.001066 EGFR, DBNL, CAV1, LYN, FER, SRC, TYK2, PTK2B, 
GSK3B, MAPK14, HIPK2, MAPK3, GAB1, PAG1 
0.032509 
GO:0009719~response to 
endogenous stimulus 
8 0.001076 CAV1, LYN, PTK2B, BCAR1, GAB1, PTPRA, PDGFRA, 
SRC 
0.031759 
GO:0031399~regulation of protein 
modification process 
7 0.001096 EGFR, DBNL, CAV1, LYN, PTK2B, PSMC2, GAB1 0.031287 
GO:0051592~response to calcium 
ion 
4 0.001362 EGFR, ACTG1, CAV1, PTK2B 0.037569 
 
PC5 (GBM10 vs GBM59) 
Increased protein expression in 10 
No significant biological categories were identified , but in the list there are some proteins involved in the EGFR 
signaling and motion (Additional Table SI), such as pMAPK3, pPxn and pYes.  
Table S12. GO protein classification of the proteins contributing to the PC6 (GBM8 vs GBM26). 
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Increased protein expression in 26 
GO Term Count pValue proteins Benjamini 
correction 
GO:0007010~cytoskeleton 
organization 
13 3.38E-08 ALDOA, TLN1, CRYAB, TLN2, BCAR1, MAP1B, ABI2, WAS, 
ITGB1, LLGL1, ACTG1, TUBB, CFL1 
2.81E-05 
GO:0006468~protein amino 
acid phosphorylation 
15 5.94E-08 FYB, LYN, TAOK1, HCK, PTPRA, ABI2, FER, MAPK12, 
GSK3B, MAPK14, HIPK2, DYRK1A, MAPK3, CFL1, GAB1 
2.47E-05 
GO:0030029~actin filament-
based process 
9 2.17E-06 ACTG1, ALDOA, TLN1, BCAR1, CFL1, ABI2, WAS, ITGB1, 
LLGL1 
0.000301 
GO:0007043~cell-cell junction 
assembly 
4 3.51E-05 TLN1, TLN2, GJA1, VCL 0.00416 
GO:0006928~cell motion 10 4.42E-05 ACTG1, TLN1, TUBB, MAPK14, BCAR1, CFL1, ANXA1, ABI2, 
ITGB1, VCL 
0.004587 
GO:0045216~cell-cell junction 
organization 
4 0.000269 TLN1, TLN2, GJA1, VCL 0.022168 
GO:0034329~cell junction 
assembly 
4 0.000432 TLN1, TLN2, GJA1, VCL 0.032164 
GO:0018212~peptidyl-tyrosine 
modification 
4 0.000689 LYN, DYRK1A, ABI2, FER 0.043139 
 
 
Table S13. GO protein classification of the proteins contributing to the PC7 (GBM12 vs GBM59). 
Decrease in GBM12/Increase in GBM59 
GO Term Count pValue proteins Benjamini 
correction 
GO:0006793~phosphorus metabolic 
process 
16 5.41E-07 EGFR, FYB, LYN, INPPL1, HCK, ABI2, ABI1, ACP1, 
EPHA2, EPHA4, MAPK12, MAPK14, CFL1, GAB1, 
SHC1, ABL2 
0.000232 
GO:0007169~transmembrane receptor 
protein tyrosine kinase signaling pathway 
9 8.99E-07 EGFR, EPS15, EPHA4, CBL, GAB1, ABI1, SHC1, 
STAT3, EPHA2 
0.000258 
GO:0016310~phosphorylation 14 2.11E-06 FYB, EGFR, LYN, HCK, ABI2, ABI1, EPHA2, 
EPHA4, MAPK12, MAPK14, CFL1, GAB1, SHC1, 
ABL2 
0.000454 
GO:0007173~epidermal growth factor 
receptor signaling pathway 
5 2.46E-06 EGFR, EPS15, CBL, GAB1, SHC1 0.000423 
GO:0030182~neuron differentiation 10 1.64E-05 EGFR, EPHA4, TUBB, SEPT2, CD44, UCHL1, ABI2, 
GJA1, STAT3, EPHA2 
0.00235 
GO:0006096~glycolysis 5 2.04E-05 ALDOA, LDHA, TPI1, PKM2, ENO1 0.002193 
GO:0046164~alcohol catabolic process 5 0.000175 ALDOA, LDHA, TPI1, PKM2, ENO1 0.010676 
GO:0019318~hexose metabolic process 6 0.000517 ALDOA, LDHA, TPI1, MAPK14, PKM2, ENO1 0.023108 
GO:0018212~peptidyl-tyrosine 
modification 
4 0.000609 LYN, ABI2, ABI1, ABL2 0.023514 
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GO:0007010~cytoskeleton organization 8 0.00071 ACTG1, ALDOA, TLN1, CAV1, TUBB, CFL1, ABI2, 
ABL2 
0.02616 
GO:0010033~response to organic 
substance 
10 0.000725 EGFR, CAV1, LYN, CD44, MAPK14, GAB1, CFL1, 
HSPB1, SHC1, STAT3 
0.025608 
GO:0048666~neuron development 7 0.001069 EGFR, EPHA4, SEPT2, CD44, UCHL1, ABI2, GJA1 0.034732 
GO:0030036~actin cytoskeleton 
organization 
6 0.001079 ACTG1, ALDOA, TLN1, CFL1, ABI2, ABL2 0.033749 
GO:0030030~cell projection organization 7 0.001628 EGFR, EPHA4, SEPT2, CD44, UCHL1, ABI2, GJA1 0.048766 
 
Increase in GBM12 
No significant biological categories were identified besides one GO category named ”cell motion”. 
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4. K-means clustering 
K-means clustering was performed using the Matlab code. The entire dataset was initially used to perform the 
clustering. Each protein was divided by its average value prior to clustering, as in Johnson et al 9 to improve 
clustering results. The data was divided into different numbers of clusters and each division was evaluated using 
Silhouette method 11. The silhouette value for each point (each protein) is a measure of how similar that point is to 
other points in its own cluster. Different cluster solutions were evaluated using the silhouette value that was 
calculated for every protein. The best clustering solution (number of clusters) was defined when the majority of the 
proteins (> 95%) had positive values. Only proteins with the silhouette values > 0.2 were analyzed further.  As 
shown in the Figure S10a there is a large number of proteins (>30%) that do not belong (negative Silhouette values, 
see Fig.S10 for more details) to the defined clusters or poorly belong (proteins with small Silhouette values < 0.2, 
~50%). Similar results were obtained when the data was divided into different number of clusters, such as 5, 8 or 
12 clusters.  
To achieve a more precise division into clusters, phosphorylated subgroup of proteins was subjected to k-means 
clustering analysis. Using phosphoproteins only we were able to obtain clusters with relatively small amount of 
proteins that did not belong to the defined clusters (Fig.S10b). Proteins with Silhouette values > 0.2 were included 
in further biological analysis. Note that silhouette value ranges from -1 to +1. A high silhouette value indicates 
that protein i is well-matched to its own cluster, and poorly-matched to neighboring clusters. In our best clustering 
solution (10 clusters) most of the phosphoproteins had positive values. However the majority of the proteins did 
not approach value +1, pointing to the inability of the method to achieve a good resolution of the GBM proteomic 
signatures. 10 centroids (centers of the clusters) are shown in the Fig. S11 and the proteins belonging to these 
clusters were classified according to the biological processes. Only clusters 6 and 10 could be classified to 
statistically significant biological  groups according to DAVID database (phosphorylation category in cluster 6 
and MAPK activity in the cluster 10 were identified as statistically enriched  groups according to EASE score and 
Benjamini correction).  
Interestingly k-means clustering yields very similar results to the affinity propagation algorithm that was utilized 
by Johnson at al. to cluster phosphorylation sites 9. Only cluster number 6 from the k-means clustering looked 
somewhat different in comparison with the results obtained by Johnson et al. 
 Every cluster included a relatively small number of the proteins with significant Silhouette values (>0.2, Table 
S14). 
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Table S14. Clustering of the phospho proteins using k-means clustering algorithm. 
Proteins with the Silhouette values > 0.2 were used to generate the table. 
cluster 1  cluster 2  cluster 3  cluster4  cluster5  
PHKA1 y511 GDI2 y203 CCDC88A  y1799 PLCG1 y481 PRAGMIN y413 
MERTK y929 EphA2 y594 WWP2 y373 GARS y453 PDLIM4 y293 
PDGFRa y731 TKT y275  SEPT7 y30 ACLY y682 SLITRK5 y945 
  EphA2 y575 CTTN y334  SEPT9 y278 DLG3 y673 
  CDK1 t14 and 
y15 
Fer y714 PARD3 y1080 Vav2 y159 
    GJA1  y313 NTRK1 y681 ANXA1 y21 
    PTK2 y397 PRUNE2 y1738   
    ZFYVE16  y1381 VIM y117   
    SDCBP y56     
    MAP1B y1062     
    ACTG1 y198     
    VIM y61     
    DPYSL2 y32     
    Tyk2 y292     
    HIPK2 y361     
    HIST1H4A y52     
    SET y146     
    SHP2 y584     
    MAPK3 y204     
    Yes1 y537     
          
cluster 6  cluster7  cluster8  cluster9  cluster10  
Gab1 y406 CTNND2 y503 ZFYVE16 y578 GRLF1 y1087+s1070 INPPL1 y1135 
PAG y163 FGFR1OP y317 C9orf86 y726 ARHGAP42 y376 ACP1 y131 
MAPK12 y185 CTNND1 y334 LANCL2 y295  SEPT7 y141 NAA10 y137 
MAPK14 y182 + 
t180 
ACTN1 y215 DDR1 y792 + 
y977 
MAPK11 y182 MPZL1  y263 + 
s260 
ANXA2 y188 CTNND1 y257   ARHGEF40 y242 HGS/Hrs y216 
ROBO1 Y1114 PSMC2 y4   LLGL1 y510 ENO1 y287 
DCBLD2 y750 PJA2 y63   CLTC y899 ACTG1 y240 
RPSA y139 CNN3 y10   FHL1 y207 ENO1 y44 
CRIP2 y77 CNN3 y320   AP3M1 y31 CTPS y473 
CGNL1 y108 AFAP1L2 y359   CLTC y1477 PIK3R2 y605 
PDGFRa y988 STIM2 y666   CAPRIN1 y78 TLN2 y1665 
MAPK1 y187 SND1 y908   ANXA1 y207 SPRY1 y53 
Abi1 y213 TRIM9 y60   FGD5 y579 PIK3AP1 y694 
VCL y822 DBN1 y597   eIF1 y30 ABL2 y439 
 SEPT2 y211 AFAP1L2 y413   CFL1 y140 CAV1 y14 
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PTPRZ1 y2179 TBCB y98   GRLF1 y1087 SPRY4 y52 
CDK1 y15 ERBB2IP y1107   FYB y571 Hck y522 
  ITGB1 y783   PITPNA y140 Gab1 y659 
  EGFR y992   GSK3b y216 + s219 SHC1 y427 
  EphA4 y779   ALDOA y3   
  PAG1 y417   FAM118B y303   
  PPP1R14B y29   Lyn y397   
  MPP5 y243   PROSC y69   
  PAG1 y387   PTPRA y798   
  DBNL y162   TLN1 y70   
  NES y925       
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5. Comparison between CGH datasets from GBM tumors and iTRAQ proteomic datasets 
To examine to what extent genomic changes have a proteomic output in GBM tumors we used CGH data 
available in GEO database (GSE39242) for GBM 12, 8,15, 26 and 59 tumors. Values representing gene copy 
numbers in the CGH experiments were normalized by the Female Reference Genome as described in (GSE39242, 
GEO). Since proteomic data was not normalized, we created two comparable datasets by dividing genomic and 
proteomic input values by the intensity values from the GBM8 tumor.  Fig.S12 shows that normalization by the 
GBM8 didn’t affect the unbalanced processes as identified using non-normalized GBM tissues.  
To compare the CGH and iTRAQ datasets we used a similar CGH gene list as in the proteomic dataset (~1424 out 
of 1770 corresponding genes were found in the CGH dataset). The CGH dataset includes several probes for every 
gene thereby creating a list of ~9000 probes for the 1424 genes. Fig.S13 represents comparison between CGH and 
iTRAQ datasets. Although  values are very similar between the proteomic and genomic datasets (Fig.S13 a 
and b), G  vectors differ in their composition. To compare between the CGH and proteomic first unbalanced 
processes we created a list of the proteins with the 0.031Gi    (101 proteins, as shown in the Fig.S13d)  and 
compared it to the gene list with 0.0151Gi   (288 genes as shown in the Fig.S13c). 29 proteins (~30%) out of 
101 proteins were found also in the genomic (as identified from the CGH dataset) first constraint. Similar result 
was obtained for the genes/ proteins with the significant 1Gi positive values ( 0.031Gi  for the proteins, and 
0.0151Gi  for the genes, Fig.S13c,d) and for the second constraint.  
Some of the genes in which genomic changes correspond to the proteomic changes are involved in significant 
cellular functions, such as glycolytic genes ENO1 and LDHA, or signal transduction regulators, as Cbl, Gab1 and 
Gab3 (Table S15). It was shown previously that genomic/transcriptomic changes may lead to a significant 
phenotypic change executed by proteins, such as a shift from apoptosis to necrosis 12.  Further understanding of 
regulation processes that in some cases result in correlations between gene copy numbers and protein levels and in 
other cases lead to the lack of correlations or even anti-correlations is required.   
Robust core 
To identify genes that did not change copy numbers (those show increase/decrease in gene copy by less than 40% 
in comparison to the reference tissue)  in different GBM tumors, we looked at the genes that have not been 
amplified/deleted in comparison with the reference female tissues (Table S16). These genes belong to the 
homeostatic biological groups, similarly to the proteomic dataset, such as protein synthesis, and mRNA 
metabolism. The overlap between the CGH and proteomic list was ~50% - twice bigger than the overlap between 
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the unbalanced biological processes.  This result suggests that homeostatic robust core has significantly less 
alterations on the both genomic and proteomic levels.   
Table S15. GO protein classification of the genes influenced by  the unbalanced processes 1   (GBM15 vs 
GBM12 and 59). 
increase in GBM12 and 59/Decrease in GBM15 
GO Term Count EASE 
score 
Genes Benjamini 
correction 
GO:0046907~intracellular 
transport 
51 1.61E-10 CLTA, CLTB, PDIA3, AP1B1, APP, RAE1, SEC24C, NUP133, OPA1, 
HSP90AA1, IPO9, ERGIC1, WAS, TIMM44, FLNA, BCAP31, 
MAPK1, TXNDC5, IPO4, F2, KPNA6, SORT1, THOC4, GNAS, 
KPNA4, SRP72, VPS26B, COPE, BID, SNX2, EEA1, TIMM13, SET, 
MACF1, AP3D1, PPP3CA, TNPO2, EHD1, UPF1, TOMM40, ARFIP1, 
AP2A2, SCFD1, ARF1, VCP, AP2A1, RAB35, PCNA, SPTBN1, 
NUTF2, SSR4 
3.6E-07 
GO:0006091~generation of 
precursor metabolites and 
energy 
30 2.16E-08 LDHA, GNPDA1, PHKA1, PGAM1, HK1, ATP6V1B2, NDUFS8, 
PDHA1, NDUFS3, ATP6V0D1, ENO1, NDUFA4, TXNL1, ACO2, 
PFKL, SLC25A4, SUCLG2, MSH2, ACO1, PFKP, DLAT, PPP1CB, 
PYGL, ATP6V1E1, PGM1, ATP5C1, GAA, TXNRD1, GNAS, PGK1 
2.41E-05 
GO:0016044~membrane 
organization 
33 4.13E-08 BID, CLTA, GNAI3, AP1B1, SAMM50, SNX2, EEA1, EPS15L1, 
TIMM13, APP, SEC24C, THBS1, EHD1, HIP1, EHD4, EGFR, 
HSP90AA1, OPA1, MRC2, LMNA, ELMO2, CORO1C, AP2A2, LRP1, 
ARF1, AP2A1, TXNDC5, RAB5A, SORT1, MERTK, COPE, EPN2, 
SH3GL1 
3.08E-05 
GO:0044275~cellular 
carbohydrate catabolic process 
15 1.06E-07 LDHA, TALDO1, GNPDA1, PFKL, PGAM1, PFKP, HK1, DLAT, 
GPD1L, PYGL, PGM1, GAA, PDHA1, PGK1, ENO1 
5.94E-05 
GO:0016192~vesicle-mediated 
transport 
41 1.54E-07 CLTA, GNAI3, CLTB, AP1B1, SNX2, EEA1, EPS15L1, LLGL1, APP, 
ACTR1A, AP3D1, RAB6A, THBS1, EHD1, SEC24C, HIP1, EHD4, 
MRC2, SCRN1, WAS, ERGIC1, FLNA, ELMO2, BCAP31, LRPAP1, 
CORO1C, AP2A2, SCFD1, LRP1, VCP, ARF1, AP2A1, TXNDC5, 
RAB35, RAB5A, CPNE1, SORT1, MERTK, COPE, SH3GL1, EPN2 
6.91E-05 
GO:0034613~cellular protein 
localization 
33 2.35E-07 BID, CLTA, CLTB, PDIA3, AP1B1, SNX2, TIMM13, MACF1, AP3D1, 
PPP3CA, SEC24C, TNPO2, EGFR, TOMM40, IPO9, ARFIP1, 
TIMM44, FLNA, BCAP31, MAPK1, AP2A2, VCP, AP2A1, IPO4, F2, 
PCNA, KPNA6, SORT1, SPTBN1, NUTF2, SRP72, KPNA4, SSR4 
8.78E-05 
GO:0070727~cellular 
macromolecule localization 
33 2.77E-07 BID, CLTA, CLTB, PDIA3, AP1B1, SNX2, TIMM13, MACF1, AP3D1, 
PPP3CA, SEC24C, TNPO2, EGFR, TOMM40, IPO9, ARFIP1, 
TIMM44, FLNA, BCAP31, MAPK1, AP2A2, VCP, AP2A1, IPO4, F2, 
PCNA, KPNA6, SORT1, SPTBN1, NUTF2, SRP72, KPNA4, SSR4 
8.86E-05 
GO:0006886~intracellular 
protein transport 
31 3.04E-07 BID, CLTA, CLTB, PDIA3, AP1B1, SNX2, TIMM13, MACF1, AP3D1, 
PPP3CA, SEC24C, TNPO2, TOMM40, IPO9, ARFIP1, TIMM44, 
BCAP31, MAPK1, AP2A2, VCP, AP2A1, IPO4, F2, PCNA, KPNA6, 
SORT1, SPTBN1, NUTF2, SRP72, KPNA4, SSR4 
8.52E-05 
GO:0046164~alcohol catabolic 
process 
14 4.14E-07 LDHA, TALDO1, GNPDA1, PFKL, PGAM1, PFKP, HK1, COMT, 
DLAT, GPD1L, PGM1, PDHA1, PGK1, ENO1 
0.000103 
GO:0030036~actin cytoskeleton 
organization 
22 1.9E-06 TLN1, CNN3, ACTA1, ROCK2, BCAR1, CAPZA2, CAPZA1, ACTN1, 
FLNB, CAPZB, WAS, LLGL1, FLNA, EPB41L2, DYNLL1, PAK2, 
PTK2B, ABL2, DBN1, PLS3, LCP1, PARVA 
0.000425 
GO:0008104~protein 
localization 
51 2.01E-06 TLN1, CLTA, CLTB, PDIA3, AP1B1, RAB5C, RAB6A, SEC24C, 
EGFR, CUTA, NUP133, G3BP2, IPO9, FLNB, TIMM44, FLNA, 
BCAP31, MAPK1, IPO4, F2, RAB5A, KPNA6, SORT1, GNAS, 
KPNA4, SRP72, VPS26B, COPE, BID, SNX2, TIMM13, MACF1, 
AP3D1, PPP3CA, TNPO2, SNX27, RRBP1, HSPG2, TOMM40, 
ARFIP1, EPS15, AP2A2, SCFD1, ARF1, VCP, AP2A1, RAB35, PCNA, 
SPTBN1, NUTF2, SSR4 
0.000409 
GO:0016052~carbohydrate 
catabolic process 
15 2.41E-06 LDHA, TALDO1, GNPDA1, PFKL, PGAM1, PFKP, HK1, DLAT, 
GPD1L, PYGL, PGM1, GAA, PDHA1, PGK1, ENO1 
0.00045 
GO:0033365~protein 
localization in organelle 
17 3.91E-06 BID, PDIA3, TOMM40, IPO9, TIMM13, TIMM44, MAPK1, MACF1, 
IPO4, F2, KPNA6, SPTBN1, NUTF2, SRP72, KPNA4, PPP3CA, 
TNPO2 
0.000673 
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GO:0046365~monosaccharide 
catabolic process 
12 4.64E-06 LDHA, GNPDA1, TALDO1, PFKL, PGM1, PGAM1, PFKP, HK1, 
PDHA1, DLAT, PGK1, ENO1 
0.000742 
GO:0006007~glucose catabolic 
process 
11 4.67E-06 LDHA, TALDO1, PFKL, PGM1, PGAM1, PFKP, HK1, PDHA1, 
DLAT, PGK1, ENO1 
0.000698 
GO:0030029~actin filament-
based process 
22 5.28E-06 TLN1, CNN3, ACTA1, ROCK2, BCAR1, CAPZA2, CAPZA1, ACTN1, 
FLNB, CAPZB, WAS, LLGL1, FLNA, EPB41L2, DYNLL1, PAK2, 
PTK2B, ABL2, DBN1, PLS3, LCP1, PARVA 
0.000739 
GO:0006096~glycolysis 10 5.71E-06 LDHA, PFKL, PGM1, PGAM1, PFKP, HK1, PDHA1, DLAT, PGK1, 
ENO1 
0.000752 
GO:0045184~establishment of 
protein localization 
45 7.01E-06 BID, CLTA, CLTB, PDIA3, AP1B1, RAB5C, SNX2, TIMM13, 
MACF1, AP3D1, RAB6A, PPP3CA, SEC24C, TNPO2, NUP133, 
SNX27, RRBP1, TOMM40, IPO9, ARFIP1, TIMM44, FLNA, BCAP31, 
EPS15, MAPK1, AP2A2, SCFD1, VCP, ARF1, AP2A1, IPO4, RAB35, 
F2, PCNA, RAB5A, KPNA6, SORT1, SPTBN1, NUTF2, GNAS, 
KPNA4, SRP72, SSR4, VPS26B, COPE 
0.000872 
GO:0010608~posttranscriptional 
regulation of gene expression 
20 9.3E-06 PRKCA, METAP1, UPF1, ACO1, RBM3, DDX1, PRKDC, ELAVL1, 
IGF2BP2, GCN1L1, RPS4X, FLNA, EIF4G1, MAPK1, APP, PTK2B, 
SND1, EIF4A2, HSPD1, THBS1 
0.001096 
GO:0015031~protein transport 44 1.27E-05 BID, CLTA, CLTB, PDIA3, AP1B1, RAB5C, SNX2, TIMM13, 
MACF1, AP3D1, RAB6A, PPP3CA, SEC24C, TNPO2, NUP133, 
SNX27, RRBP1, TOMM40, IPO9, ARFIP1, TIMM44, BCAP31, EPS15, 
MAPK1, AP2A2, SCFD1, VCP, ARF1, AP2A1, RAB35, IPO4, F2, 
PCNA, RAB5A, KPNA6, SORT1, SPTBN1, NUTF2, GNAS, KPNA4, 
SRP72, SSR4, VPS26B, COPE 
0.001418 
GO:0043085~positive regulation 
of catalytic activity 
34 1.35E-05 PARD3, GNAI2, PTPLAD1, GNA11, PSMA7, PSMB5, PTK2B, ILK, 
PSMD2, SHC1, THBS1, HIP1, EGFR, MSH6, MSH2, VAV2, PPP1CB, 
PSMB8, THY1, PSMA2, PSMC6, PSMD13, LRP1, VCP, GNB1, 
PSME2, NTRK1, PSMC1, F2, PPP2R4, GNAS, HSPD1, ABL2, GAP43 
0.001438 
GO:0010324~membrane 
invagination 
20 1.68E-05 AP1B1, MRC2, SNX2, EPS15L1, EEA1, ELMO2, CORO1C, APP, 
AP2A2, LRP1, AP2A1, RAB5A, SORT1, MERTK, EHD1, THBS1, 
HIP1, EHD4, SH3GL1, EPN2 
0.001708 
GO:0006897~endocytosis 20 1.68E-05 AP1B1, MRC2, SNX2, EPS15L1, EEA1, ELMO2, CORO1C, APP, 
AP2A2, LRP1, AP2A1, RAB5A, SORT1, MERTK, EHD1, THBS1, 
HIP1, EHD4, SH3GL1, EPN2 
0.001708 
GO:0017038~protein import 15 2.09E-05 BID, PDIA3, TOMM40, IPO9, TIMM13, TIMM44, MAPK1, IPO4, F2, 
SPTBN1, KPNA6, NUTF2, KPNA4, PPP3CA, TNPO2 
0.002035 
GO:0019320~hexose catabolic 
process 
11 2.31E-05 LDHA, TALDO1, PFKL, PGM1, PGAM1, PFKP, HK1, PDHA1, 
DLAT, PGK1, ENO1 
0.002151 
GO:0006414~translational 
elongation 
13 2.82E-05 RPL35, EEF2, VARS, RPS4X, RPS25, RPS19, RPS28, RPL22, RPL3, 
EEF1G, RPL10, RPS10, EEF1D 
0.002523 
GO:0006006~glucose metabolic 
process 
16 3E-05 LDHA, TALDO1, PFKL, PHKA1, PGAM1, PFKP, HK1, DLAT, 
PPP1CB, CPT1A, PYGL, PGM1, GAA, PDHA1, PGK1, ENO1 
0.002578 
GO:0007015~actin filament 
organization 
11 3.37E-05 PAK2, ACTA1, PTK2B, BCAR1, ACTN1, ABL2, WAS, DBN1, PLS3, 
FLNA, LCP1 
0.002795 
GO:0006913~nucleocytoplasmic 
transport 
16 3.76E-05 NUP133, UPF1, PDIA3, IPO9, MAPK1, SET, RAE1, IPO4, F2, 
KPNA6, SPTBN1, THOC4, NUTF2, KPNA4, PPP3CA, TNPO2 
0.003007 
GO:0051169~nuclear transport 16 4.37E-05 NUP133, UPF1, PDIA3, IPO9, MAPK1, SET, RAE1, IPO4, F2, 
KPNA6, SPTBN1, THOC4, NUTF2, KPNA4, PPP3CA, TNPO2 
0.003368 
GO:0044093~positive regulation 
of molecular function 
35 6.21E-05 PARD3, GNAI2, PTPLAD1, GNA11, PRDX3, PSMA7, PSMB5, 
PTK2B, ILK, PSMD2, SHC1, THBS1, HIP1, EGFR, MSH6, MSH2, 
VAV2, PPP1CB, PSMB8, THY1, PSMA2, PSMC6, PSMD13, LRP1, 
VCP, GNB1, PSME2, NTRK1, PSMC1, F2, PPP2R4, GNAS, HSPD1, 
ABL2, GAP43 
0.004626 
GO:0005996~monosaccharide 
metabolic process 
19 6.43E-05 LDHA, TALDO1, GNPDA1, PFKL, PHKA1, PGAM1, PFKP, HK1, 
DLAT, NAGK, PPP1CB, CPT1A, PYGL, PGM1, GAA, PDHA1, 
PGK1, ENO1, PRPS1 
0.004633 
GO:0006412~translation 24 7.34E-05 EGFR, YARS, CARS, RRBP1, RBM3, RPL35, EEF2, QARS, LRRC47, 
VARS, RPS4X, RPS25, EIF4G1, RPS19, RPS28, RPL22, EIF1AX, 
EIF4A2, RPL3, RPL10, EEF1G, RPS10, EIF2AK2, EEF1D 
0.005127 
GO:0006417~regulation of 
translation 
14 0.000141 PRKCA, METAP1, UPF1, ACO1, DDX1, IGF2BP2, RPS4X, GCN1L1, 
EIF4G1, MAPK1, APP, PTK2B, EIF4A2, THBS1 
0.009509 
GO:0043161~proteasomal 
ubiquitin-dependent protein 
catabolic process 
12 0.000147 PSMA2, PSMB5, CUL3, PSMC6, PSMD13, VCP, PSME2, PSMC1, 
PSMD2, PSMA7, STUB1, PSMB8 
0.009644 
GO:0010498~proteasomal 
protein catabolic process 
12 0.000147 PSMA2, PSMB5, CUL3, PSMC6, PSMD13, VCP, PSME2, PSMC1, 
PSMD2, PSMA7, STUB1, PSMB8 
0.009644 
GO:0065003~macromolecular 
complex assembly 
37 0.000153 PARD3, SAMM50, CAPZA2, CAPZA1, H1FX, CDH2, HPRT1, 
LLGL1, SET, PAK2, PTK2B, PRMT5, ILK, NDUFS8, TUBB6, 
H2AFX, TNPO2, HIP1, CUTA, HSP90AA1, PFKL, DDX1, PFKP, 
0.009729 
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IPO9, MCM2, MBNL1, SLC9A3R1, SF3A2, WAS, HMGA1, FLNA, 
PTRF, VCP, IPO4, CAPG, HSPD1, PARVA 
GO:0006606~protein import 
into nucleus 
11 0.000157 MAPK1, PDIA3, IPO4, F2, KPNA6, SPTBN1, IPO9, NUTF2, PPP3CA, 
KPNA4, TNPO2 
0.009699 
GO:0016310~phosphorylation 42 0.000171 PRPF4B, GNAI2, PTPLAD1, PRDX4, PRKDC, CASK, ABI1, CAD, 
FER, ATP6V1B2, TOP1, APP, PAK2, PTK2B, ILK, NDUFS8, SHC1, 
NDUFS3, ATP6V0D1, THBS1, NDUFA4, EGFR, PRKCA, TAOK1, 
ROCK2, MSH2, MAP2K2, PTPRA, TRIM28, AK3, EPHA2, MAPK1, 
NTRK1, ATP6V1E1, DYRK1A, F2, ATP5C1, SPTBN1, MERTK, 
PGK1, EIF2AK2, ABL2 
0.010278 
 
decrease in GBM12 and 59/ Increase in GBM15 
GO Term Count EASE 
score 
Genes Benjamini 
correction 
GO:0006084~acetyl-CoA 
metabolic process 
9 1.07E-07 SDHA, NNT, ACO2, DLD, CS, IDH2, SUCLA2, IDH3A, MDH2 0.000218 
GO:0046356~acetyl-CoA 
catabolic process 
8 1.97E-07 SDHA, NNT, ACO2, CS, IDH2, SUCLA2, IDH3A, MDH2 0.0002 
GO:0006099~tricarboxylic 
acid cycle 
8 1.97E-07 SDHA, NNT, ACO2, CS, IDH2, SUCLA2, IDH3A, MDH2 0.0002 
GO:0009109~coenzyme 
catabolic process 
8 5.02E-07 SDHA, NNT, ACO2, CS, IDH2, SUCLA2, IDH3A, MDH2 0.00034 
GO:0008104~protein 
localization 
40 1.53E-06 AP1M1, TLN1, TLN2, PML, NUP93, NAPA, TIMM50, LMAN2, CLTC, 
CDC37, CTNNB1, TMED2, NPM1, PPP3CA, TPR, TNPO1, KPNB1, 
AP3B1, EGFR, SEC23A, ARHGEF2, ACTN4, RRBP1, YWHAB, HSPG2, 
ITGA2, ATG3, FLNB, FLNA, RAB31, AP2A2, ERBB2IP, AP2A1, 
FGFR1OP, RAB35, SDCBP, NUTF2, PDCD6IP, YKT6, COPE 
0.000778 
GO:0051187~cofactor 
catabolic process 
8 1.84E-06 SDHA, NNT, ACO2, CS, IDH2, SUCLA2, IDH3A, MDH2 0.00075 
GO:0046907~intracellular 
transport 
33 1.99E-06 NCBP1, AP1M1, PML, NAPA, CLTC, TPM1, CDC37, SLC1A3, NPM1, 
RANBP1, PPP3CA, TPR, TNPO1, KPNB1, AP3B1, SEC23A, ARHGEF2, 
HSP90AA1, MAP2K1, YWHAB, FLNA, AP2A2, SLC25A13, ERBB2IP, 
AP2A1, RAB35, TXNDC5, SDCBP, NUTF2, YKT6, COPE, DNM2, 
MYH10 
0.000675 
GO:0045333~cellular 
respiration 
12 3.08E-06 SDHA, NNT, NDUFS4, SLC1A3, SLC25A13, ACO2, DLD, CS, IDH2, 
SUCLA2, IDH3A, MDH2 
0.000895 
GO:0006091~generation of 
precursor metabolites and 
energy 
21 3.83E-06 ACOX1, PFKL, ACO2, CS, CYC1, UQCRFS1, IDH3A, SDHA, ACADVL, 
NNT, SLC1A3, SLC25A13, NDUFS4, PKM2, TXN, DLD, IDH2, 
ATP6V0A1, ATP5I, SUCLA2, MDH2 
0.000972 
GO:0009060~aerobic 
respiration 
8 4.41E-06 SDHA, NNT, ACO2, CS, IDH2, SUCLA2, IDH3A, MDH2 0.000996 
GO:0010033~response to 
organic substance 
34 5.18E-06 PTGS1, PML, PRKDC, HSPA1A, ASNS, UQCRFS1, CTNNB1, GOT2, 
CASP3, PRKAR2A, GSTM3, NDUFS4, CD44, PTK2B, GSN, GAB1, 
HSPE1, PPP3CA, NUDC, EGFR, PRKCA, HSP90AA1, MAP2K1, PFKL, 
AARS, ITGA2, STAT3, DDR1, HDAC2, GNB2, TFRC, ABAT, PEBP1, 
HSPD1 
0.001054 
GO:0032268~regulation of 
cellular protein metabolic 
process 
26 7.4E-06 NCBP1, PTPLAD1, PML, GCN1L1, PRKAR2A, NDUFS4, PTK2B, 
GAB1, QKI, PSMD3, PSMD5, PSMD7, BUB3, PSMD9, PRKCA, EGFR, 
DBNL, PAIP1, YWHAB, ITGA2, RPS5, PSMC6, HDAC2, PSMC3, 
PSMA4, PEBP1 
0.001367 
GO:0007010~cytoskeleton 
organization 
24 1.72E-05 HRAS, ARHGEF2, TLN1, CAP2, ACTN4, TLN2, TPM1, FLNB, FLNA, 
LLGL1, CTNNB1, CORO2B, PFN2, PTK2, PAK2, ERBB2IP, PTK2B, 
GSN, FGFR1OP, NPM1, RHOA, SDCBP, RANBP1, MYH10 
0.002908 
GO:0065003~macromolecular 
complex assembly 
31 1.9E-05 NCBP1, HRAS, PARD3, PML, LLGL1, CTNNB1, PTK2, NDUFS4, 
PAK2, PTK2B, GSN, NPM1, H2AFY, KPNB1, TNPO1, TUBB3, HIP1, 
HSP90AA1, PFKL, MAP2K1, YWHAB, EPRS, MCM2, SF3A1, FLNA, 
PRPF6, TBCA, CAPG, PEBP1, HSPD1, LAMC1 
0.002965 
GO:0016044~membrane 
organization 
22 2.11E-05 EGFR, SEC23A, DBNL, HRAS, AP1M1, HSP90AA1, LMNA, NAPA, 
TIMM50, EPS15L1, CLTC, ELMO2, LETM1, AP2A2, TFRC, AP2A1, 
TXNDC5, COPE, MYH10, DNM2, AP3B1, HIP1 
0.003066 
GO:0070271~protein 
complex biogenesis 
26 2.15E-05 HRAS, PARD3, PML, LLGL1, CTNNB1, PTK2, NDUFS4, PAK2, 
PTK2B, GSN, NPM1, KPNB1, TNPO1, TUBB3, HIP1, HSP90AA1, 
PFKL, MAP2K1, YWHAB, EPRS, FLNA, TBCA, CAPG, PEBP1, HSPD1, 
LAMC1 
0.002912 
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GO:0006461~protein 
complex assembly 
26 2.15E-05 HRAS, PARD3, PML, LLGL1, CTNNB1, PTK2, NDUFS4, PAK2, 
PTK2B, GSN, NPM1, KPNB1, TNPO1, TUBB3, HIP1, HSP90AA1, 
PFKL, MAP2K1, YWHAB, EPRS, FLNA, TBCA, CAPG, PEBP1, HSPD1, 
LAMC1 
0.002912 
GO:0031399~regulation of 
protein modification process 
19 2.2E-05 PRKCA, EGFR, DBNL, PTPLAD1, YWHAB, PML, PRKAR2A, PSMC6, 
NDUFS4, PTK2B, PSMC3, PSMA4, GAB1, PEBP1, PSMD3, PSMD5, 
PSMD7, BUB3, PSMD9 
0.002797 
GO:0015980~energy 
derivation by oxidation of 
organic compounds 
13 2.7E-05 ACO2, CS, IDH3A, ACADVL, SDHA, SLC25A13, NDUFS4, SLC1A3, 
NNT, DLD, IDH2, SUCLA2, MDH2 
0.00323 
GO:0043085~positive 
regulation of catalytic activity 
26 3.49E-05 PARD3, PTPLAD1, PML, TPM1, PRKAR2A, PTK2B, NPM1, GAB1, 
PSMD3, HSPE1, PSMD5, PSMD7, PSMD9, HIP1, EGFR, DBNL, CAP2, 
SSBP1, MAP2K1, YWHAB, ITGA2, VAV2, PSMC6, PSMC3, PSMA4, 
HSPD1 
0.003933 
GO:0030036~actin 
cytoskeleton organization 
16 4.12E-05 HRAS, TLN1, ARHGEF2, ACTN4, TPM1, FLNB, FLNA, LLGL1, 
CORO2B, PFN2, PAK2, PTK2B, GSN, RHOA, SDCBP, MYH10 
0.004396 
GO:0043648~dicarboxylic 
acid metabolic process 
7 4.63E-05 SDHA, GOT2, DLD, CS, IDH3A, MDH2, PC 0.004693 
GO:0045184~establishment 
of protein localization 
33 4.84E-05 AP1M1, PML, NUP93, NAPA, TIMM50, LMAN2, CLTC, CDC37, 
TMED2, NPM1, PPP3CA, TPR, TNPO1, KPNB1, AP3B1, SEC23A, 
ARHGEF2, ACTN4, RRBP1, YWHAB, ITGA2, ATG3, FLNA, RAB31, 
AP2A2, ERBB2IP, AP2A1, RAB35, SDCBP, NUTF2, PDCD6IP, YKT6, 
COPE 
0.004679 
GO:0006732~coenzyme 
metabolic process 
13 4.93E-05 COASY, ACO2, CS, IDH3A, MTHFD1, SDHA, GSR, PGLS, NNT, DLD, 
IDH2, SUCLA2, MDH2 
0.004544 
GO:0007049~cell cycle 33 5.71E-05 PPP6C, PARD3, KIAA0174, PML, SART1, CTNNB1, NUMA1, NPM1, 
PSMD3, RANBP1, PPP3CA, PSMD5, PSMD7, STAG2, BUB3, TUBB3, 
NUDC, PSMD9, EGFR, ARHGEF2, MAP2K1, ANXA1, UBE2I, MCM2, 
ARL3, PPM1G, PSMC6, ERBB2IP, PSMC3, PSMA4, PDCD6IP, DNM2, 
MYH10 
0.005034 
GO:0043933~macromolecular 
complex subunit organization 
31 6.38E-05 NCBP1, HRAS, PARD3, PML, LLGL1, CTNNB1, PTK2, NDUFS4, 
PAK2, PTK2B, GSN, NPM1, H2AFY, KPNB1, TNPO1, TUBB3, HIP1, 
HSP90AA1, PFKL, MAP2K1, YWHAB, EPRS, MCM2, SF3A1, FLNA, 
PRPF6, TBCA, CAPG, PEBP1, HSPD1, LAMC1 
0.005392 
GO:0034613~cellular protein 
localization 
22 6.38E-05 EGFR, SEC23A, ARHGEF2, AP1M1, YWHAB, PML, NAPA, CLTC, 
FLNA, CDC37, CTNNB1, AP2A2, ERBB2IP, AP2A1, NPM1, SDCBP, 
NUTF2, PPP3CA, TPR, TNPO1, KPNB1, AP3B1 
0.00518 
GO:0070727~cellular 
macromolecule localization 
22 6.94E-05 EGFR, SEC23A, ARHGEF2, AP1M1, YWHAB, PML, NAPA, CLTC, 
FLNA, CDC37, CTNNB1, AP2A2, ERBB2IP, AP2A1, NPM1, SDCBP, 
NUTF2, PPP3CA, TPR, TNPO1, KPNB1, AP3B1 
0.005415 
GO:0030029~actin filament-
based process 
16 8.56E-05 HRAS, TLN1, ARHGEF2, ACTN4, TPM1, FLNB, FLNA, LLGL1, 
CORO2B, PFN2, PAK2, PTK2B, GSN, RHOA, SDCBP, MYH10 
0.006425 
GO:0044093~positive 
regulation of molecular 
function 
27 9.25E-05 PARD3, PTPLAD1, PML, TPM1, PRKAR2A, PTK2B, NPM1, GAB1, 
PSMD3, HSPE1, PSMD5, PSMD7, PSMD9, HIP1, EGFR, DBNL, CAP2, 
ACTN4, SSBP1, MAP2K1, YWHAB, ITGA2, VAV2, PSMC6, PSMC3, 
PSMA4, HSPD1 
0.006695 
GO:0031400~negative 
regulation of protein 
modification process 
11 0.000118 PRKCA, PSMC6, PSMC3, PSMA4, YWHAB, PSMD3, PEBP1, PSMD5, 
PSMD7, BUB3, PSMD9 
0.008256 
GO:0022402~cell cycle 
process 
26 0.000132 PPP6C, PML, SART1, CTNNB1, NUMA1, NPM1, PSMD3, RANBP1, 
PSMD5, PPP3CA, PSMD7, BUB3, TUBB3, NUDC, STAG2, PSMD9, 
EGFR, ARHGEF2, MAP2K1, UBE2I, PPM1G, PSMC6, PSMC3, PSMA4, 
MYH10, DNM2 
0.008921 
GO:0032507~maintenance of 
protein location in cell 
7 0.000138 TLN1, TLN2, FGFR1OP, YWHAB, PML, FLNB, FLNA 0.009002 
GO:0055114~oxidation 
reduction 
28 0.000151 ACOX1, PTGS1, CYC1, COX5A, UQCRFS1, FDFT1, MTHFD1, GSR, 
SLC1A3, NDUFS4, PLOD1, DHCR7, PLOD3, IDH2, HSD17B4, 
IMPDH2, GPD2, IDH3A, SDHA, ACADVL, NNT, SLC25A13, HSDL2, 
BLVRB, TXN, DLD, MDH2, ALDH9A1 
0.009523 
GO:0043161~proteasomal 
ubiquitin-dependent protein 
catabolic process 
10 0.000178 RAD23B, PSMC6, PSMC3, PSMA4, RAD23A, PSMD3, PSMD5, PSMD7, 
BUB3, PSMD9 
0.01094 
 
 
Table S16.  GO classification of the genes with no change in copy number (first 50 categories). 
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GO Term Count EASE 
score 
Genes Benjamini 
correction 
GO:0046907~intracellular 
transport 
86 1.82E-
18 
NCBP1, XPO1, ENAH, CLTB, AP1B1, AP1G1, CLTC, SSR1, AP2B1, APP, 
SLC1A3, RAE1, ZFYVE16, ANP32A, ATP5O, RANBP1, SAR1B, AP3B1, 
SEC23A, NUP133, ARHGEF2, HSP90AA1, ERP29, IPO9, MYH9, ERGIC1, 
MAPK1, IPO7, TXNDC5, ARCN1, F2, RAB14, KPNA6, SDCBP, GNAS, 
SRP72, KPNA4, VPS26B, LRPPRC, MYL6, YWHAZ, NUP98, STX7, 
NUP160, COPZ1, MYL1, PML, AKAP12, SNX2, SNX1, EEA1, CALR, TPM1, 
CDC37, STX12, MACF1, NPM1, AP3D1, TMED10, VPS35, PAFAH1B1, 
PPP3CA, EHD1, HSPA8, SEC61A1, FYB, MAP2K1, ARFIP1, NUP155, 
YWHAE, AP2A2, YWHAH, ATP2A2, VCP, ERBB2IP, AP2A1, TOMM70A, 
GSK3B, BAX, RAB35, YWHAQ, SPTBN1, XPO7, YKT6, MYH10, DNM2 
5.27E-15 
GO:0008104~protein 
localization 
96 4.3E-
15 
XPO1, CLTB, AP1B1, RAB5B, AP1G1, TLN2, PDIA4, CLTC, CANX, 
RAB1A, SSR1, CTNNB1, AP2B1, ZFYVE16, RAB6A, SAR1B, RAB21, 
AP3B1, SEC23A, NUP133, ARHGEF2, LYN, ACTN4, ERP29, G3BP2, IPO9, 
MYH9, FLNB, MAPK1, RAB18, IPO7, FGFR1OP, ARCN1, F2, RAB5A, 
RAB14, KPNA6, SDCBP, GNAS, SRP72, PDCD6IP, COL1A1, KPNA4, 
RAB10, VPS26B, VPS29, YWHAZ, CAV1, NUP98, NACA, STX7, NUP160, 
COPZ1, PML, AKAP12, SNX2, SNX1, RDX, ARF5, SNX3, LMAN2, CALR, 
CDC37, STX12, TMED2, MACF1, DDX19A, NPM1, TMED10, AP3D1, 
VPS35, PPP3CA, SEC61A1, FYB, HSPG2, ITGA2, ARFIP1, NUP155, 
YWHAE, RAB31, HSP90B1, AP2A2, YWHAH, VCP, ERBB2IP, AP2A1, 
TOMM70A, GSK3B, BAX, RAB35, ARF4, YWHAQ, SPTBN1, FAF1, XPO7, 
YKT6 
6.28E-12 
GO:0045184~establishment 
of protein localization 
86 3.37E-
14 
XPO1, CLTB, AP1B1, RAB5B, AP1G1, PDIA4, CLTC, CANX, RAB1A, SSR1, 
AP2B1, ZFYVE16, RAB6A, SAR1B, RAB21, AP3B1, SEC23A, NUP133, 
ARHGEF2, LYN, ACTN4, ERP29, IPO9, MYH9, MAPK1, RAB18, IPO7, 
ARCN1, F2, RAB5A, RAB14, KPNA6, SDCBP, GNAS, SRP72, PDCD6IP, 
COL1A1, KPNA4, VPS26B, RAB10, VPS29, YWHAZ, NUP98, NACA, STX7, 
NUP160, COPZ1, PML, AKAP12, SNX2, SNX1, ARF5, SNX3, LMAN2, 
CALR, CDC37, STX12, TMED2, MACF1, DDX19A, NPM1, AP3D1, 
TMED10, VPS35, PPP3CA, SEC61A1, FYB, ITGA2, ARFIP1, NUP155, 
YWHAE, RAB31, HSP90B1, AP2A2, YWHAH, VCP, ERBB2IP, AP2A1, 
TOMM70A, GSK3B, RAB35, ARF4, YWHAQ, SPTBN1, XPO7, YKT6 
3.27E-11 
GO:0015031~protein 
transport 
85 5.64E-
14 
XPO1, CLTB, AP1B1, RAB5B, AP1G1, PDIA4, CLTC, CANX, RAB1A, SSR1, 
AP2B1, ZFYVE16, RAB6A, SAR1B, RAB21, AP3B1, SEC23A, NUP133, 
ARHGEF2, LYN, ACTN4, ERP29, IPO9, MYH9, MAPK1, RAB18, IPO7, 
ARCN1, F2, RAB5A, RAB14, KPNA6, SDCBP, GNAS, SRP72, PDCD6IP, 
COL1A1, KPNA4, VPS26B, RAB10, VPS29, YWHAZ, NUP98, NACA, STX7, 
NUP160, COPZ1, PML, AKAP12, SNX2, SNX1, ARF5, SNX3, LMAN2, 
CALR, CDC37, STX12, TMED2, MACF1, DDX19A, NPM1, AP3D1, 
TMED10, VPS35, PPP3CA, SEC61A1, FYB, ARFIP1, NUP155, YWHAE, 
RAB31, HSP90B1, AP2A2, YWHAH, VCP, ERBB2IP, AP2A1, TOMM70A, 
GSK3B, RAB35, ARF4, YWHAQ, SPTBN1, XPO7, YKT6 
4.09E-11 
GO:0006886~intracellular 
protein transport 
51 1.13E-
11 
XPO1, CLTB, AP1B1, AP1G1, CLTC, SSR1, AP2B1, ZFYVE16, SAR1B, 
AP3B1, SEC23A, ARHGEF2, ERP29, IPO9, MAPK1, IPO7, F2, ARCN1, 
KPNA6, SDCBP, KPNA4, SRP72, NUP98, YWHAZ, STX7, COPZ1, SNX2, 
AKAP12, PML, SNX1, CALR, CDC37, STX12, MACF1, NPM1, AP3D1, 
PPP3CA, SEC61A1, FYB, ARFIP1, YWHAE, AP2A2, YWHAH, ERBB2IP, 
VCP, AP2A1, TOMM70A, GSK3B, YWHAQ, SPTBN1, XPO7 
6.58E-09 
GO:0070727~cellular 
macromolecule localization 
54 1.44E-
11 
XPO1, CLTB, AP1B1, AP1G1, CLTC, CTNNB1, SSR1, AP2B1, ZFYVE16, 
SAR1B, AP3B1, SEC23A, ARHGEF2, ERP29, IPO9, MAPK1, IPO7, F2, 
ARCN1, KPNA6, SDCBP, KPNA4, SRP72, YWHAZ, NUP98, STX7, COPZ1, 
SNX2, AKAP12, PML, SNX1, CALR, CDC37, STAU1, STX12, MACF1, 
NPM1, AP3D1, PPP3CA, SEC61A1, FYB, ARFIP1, YWHAE, AP2A2, 
YWHAH, ERBB2IP, VCP, AP2A1, TOMM70A, GSK3B, BAX, YWHAQ, 
SPTBN1, XPO7 
6.97E-09 
GO:0034613~cellular protein 
localization 
53 3.54E-
11 
XPO1, CLTB, AP1B1, AP1G1, CLTC, CTNNB1, SSR1, AP2B1, ZFYVE16, 
SAR1B, AP3B1, SEC23A, ARHGEF2, ERP29, IPO9, MAPK1, IPO7, F2, 
ARCN1, KPNA6, SDCBP, KPNA4, SRP72, NUP98, YWHAZ, STX7, COPZ1, 
SNX2, AKAP12, PML, SNX1, CALR, CDC37, STX12, MACF1, NPM1, 
AP3D1, PPP3CA, SEC61A1, FYB, ARFIP1, YWHAE, AP2A2, YWHAH, 
ERBB2IP, VCP, AP2A1, TOMM70A, GSK3B, BAX, YWHAQ, SPTBN1, 
XPO7 
1.47E-08 
GO:0006091~generation of 
precursor metabolites and 
energy 
45 3.89E-
11 
UQCRC2, NDUFS4, GOT1, SLC1A3, SLC25A3, IDH2, IDH1, ATP5O, CAT, 
ERO1L, NDUFS3, ATP6V0D1, ETFB, NDUFS1, ETFA, DLST, ACO2, PFKL, 
MSH2, SUCLG2, NDUFA9, SUCLG1, CS, DLAT, PFKM, PPP1CB, SOD2, 
SDHA, ATP6V1A, NNT, GBE1, UQCRH, PYGL, GSK3B, PKM2, GFPT1, 
1.41E-08 
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ATP6V1E1, TXN, PGM1, ATP6V0A1, TXNRD1, GNAS, ATP5A1, UQCRB, 
MDH1 
GO:0015980~energy 
derivation by oxidation of 
organic compounds 
27 2.1E-
09 
UQCRC2, SLC1A3, NDUFS4, GOT1, IDH2, IDH1, CAT, NDUFS3, NDUFS1, 
DLST, ACO2, SUCLG2, NDUFA9, SUCLG1, CS, PPP1CB, SOD2, SDHA, 
GBE1, NNT, PYGL, UQCRH, GFPT1, GSK3B, GNAS, UQCRB, MDH1 
6.77E-07 
GO:0009060~aerobic 
respiration 
14 2.32E-
09 
UQCRC2, DLST, ACO2, SUCLG2, SUCLG1, CS, SDHA, NNT, UQCRH, 
IDH2, IDH1, CAT, MDH1, UQCRB 
6.72E-07 
GO:0051493~regulation of 
cytoskeleton organization 
25 1.4E-
08 
XPO1, LIMA1, CAV1, RDX, CAPZB, TPM1, CTNNB1, ACTR3, MACF1, 
ARPC2, RAC1, NPM1, RHOA, RANBP1, ARHGEF2, ROCK2, MAP1B, 
ARPC1A, ARPC1B, ARPC5L, CAPG, MAP2, MAP4, SPTBN1, SPTAN1 
3.69E-06 
GO:0043933~macromolecular 
complex subunit organization 
68 1.8E-
08 
NCBP1, XPO1, HP1BP3, SNRPD3, NAP1L1, SNRPD1, NAP1L4, CTNNB1, 
PICALM, NDUFS4, H2AFV, H2AFY, CAT, NUP133, PPP2R1A, HSP90AA1, 
DARS, PFKL, CRYAB, SF1, IPO9, MBNL1, DECR1, PFKM, SPAG9, IPO7, 
UQCRH, TBCA, RPS14, RRM1, SMARCA5, SNRPC, LAMC1, XRN2, PPP5C, 
PARVA, PARD3, NUP98, CAV1, FKBP4, PML, ABI2, CDH2, CALR, SF3B3, 
PXN, FGG, PTK2, PTK2B, FGB, USP39, NPM1, RAC1, HIP1, MAP2K1, 
DDX1, EPRS, SMAD2, ANXA5, ETF1, SF3A1, SF3A3, SOD2, VCP, BAX, 
THRAP3, CAPG, XPO7 
4.36E-06 
GO:0065003~macromolecular 
complex assembly 
64 4.31E-
08 
NCBP1, XPO1, HP1BP3, SNRPD3, NAP1L1, SNRPD1, NAP1L4, CTNNB1, 
PICALM, NDUFS4, H2AFV, H2AFY, CAT, PPP2R1A, HSP90AA1, DARS, 
PFKL, CRYAB, SF1, IPO9, MBNL1, DECR1, PFKM, SPAG9, IPO7, UQCRH, 
TBCA, RPS14, RRM1, SMARCA5, SNRPC, LAMC1, PARVA, PPP5C, 
PARD3, NUP98, CAV1, FKBP4, PML, CDH2, CALR, SF3B3, PXN, PTK2, 
FGG, PTK2B, FGB, USP39, NPM1, RAC1, HIP1, MAP2K1, DDX1, EPRS, 
SMAD2, ANXA5, SF3A1, SF3A3, SOD2, VCP, BAX, THRAP3, CAPG, XPO7 
9.62E-06 
GO:0034621~cellular 
macromolecular complex 
subunit organization 
42 7.31E-
08 
XPO1, NCBP1, NUP98, CAV1, HP1BP3, FKBP4, SNRPD3, SNRPD1, 
NAP1L1, ABI2, CALR, NAP1L4, PXN, PTK2, FGG, NDUFS4, PICALM, 
H2AFV, PTK2B, FGB, USP39, RAC1, NPM1, H2AFY, HIP1, NUP133, 
HSP90AA1, DDX1, SF1, IPO9, SMAD2, MBNL1, ETF1, SF3A1, SF3A3, 
TBCA, IPO7, RPS14, SMARCA5, SNRPC, XPO7, XRN2 
1.52E-05 
GO:0006412~translation 40 7.7E-
08 
RPL18, NACA, EEF1B2, RPL19, RPL14, NARS, PABPC4, EIF5B, IGF2BP3, 
VARS, KARS, IARS, WARS, RPS26, RPL31, RPS3A, RPL34, RPL8, LARS, 
RPL5, RPL10A, RPL4, YARS, DARS, AARS, EPRS, LRRC47, ETF1, EIF4B, 
EIF4G2, RPS18, RPL18A, RPS16, TSFM, RPS14, EIF2S1, RARS, RPS12, 
RPS13, EIF2AK2 
1.49E-05 
GO:0045333~cellular 
respiration 
20 8.08E-
08 
UQCRC2, DLST, ACO2, SUCLG2, NDUFA9, SUCLG1, CS, SOD2, SDHA, 
NNT, NDUFS4, SLC1A3, UQCRH, IDH2, IDH1, CAT, NDUFS3, NDUFS1, 
UQCRB, MDH1 
1.47E-05 
GO:0006397~mRNA 
processing 
39 1.01E-
07 
RALY, NCBP1, PRPF4B, STRAP, NHP2L1, SNRPD3, RBM4, LSM7, 
SNRPD1, SYNCRIP, HNRPLL, SF3B3, PNN, PRPF19, SF3B1, APP, DDX46, 
PRPF8, PCBP2, NUDT21, DNAJC8, USP39, DHX15, U2AF1, LSM3, PABPC1, 
KHDRBS3, EFTUD2, PTBP1, DDX1, SF1, MBNL1, SF3A1, PRPF4, SF3A3, 
CPSF6, SNRPC, XRN2, ADAR 
1.72E-05 
GO:0006414~translational 
elongation 
20 1.59E-
07 
RPL18, RPL19, EEF1B2, RPL14, VARS, RPS26, RPS18, RPS16, RPL18A, 
RPS3A, RPL31, RPL34, RPS14, TSFM, RPL8, RPS12, RPS13, RPL5, RPL4, 
RPL10A 
2.56E-05 
GO:0010498~proteasomal 
protein catabolic process 
20 1.87E-
07 
RAD23B, RAD23A, PSMA7, CUL3, PSMA1, HSP90B1, PSMB7, VCP, 
PSMD12, PSMD11, PSMB3, PSMA4, PSMD1, PSMC1, PSMA3, PSMD3, 
PSME3, FAF1, PSMD6, PSMD9 
2.85E-05 
GO:0043161~proteasomal 
ubiquitin-dependent protein 
catabolic process 
20 1.87E-
07 
RAD23B, RAD23A, PSMA7, CUL3, PSMA1, HSP90B1, PSMB7, VCP, 
PSMD12, PSMD11, PSMB3, PSMA4, PSMD1, PSMC1, PSMA3, PSMD3, 
PSME3, FAF1, PSMD6, PSMD9 
2.85E-05 
GO:0034622~cellular 
macromolecular complex 
assembly 
38 2.31E-
07 
XPO1, NCBP1, NUP98, CAV1, HP1BP3, SNRPD3, FKBP4, SNRPD1, 
NAP1L1, CALR, NAP1L4, PXN, PTK2, FGG, NDUFS4, PICALM, H2AFV, 
FGB, PTK2B, RAC1, NPM1, USP39, H2AFY, HIP1, HSP90AA1, DDX1, SF1, 
SMAD2, IPO9, MBNL1, SF3A1, SF3A3, TBCA, IPO7, RPS14, SMARCA5, 
SNRPC, XPO7 
3.35E-05 
GO:0016192~vesicle-
mediated transport 
56 2.53E-
07 
CLTB, AP1B1, AP1G1, EPS15L1, CLTC, RAB1A, CTNNB1, AP2B1, APP, 
PICALM, ZFYVE16, RAB6A, SAR1B, AP3B1, SEC23A, LYN, ERGIC1, 
RAB18, TXNDC5, ARCN1, RAB5A, RAB14, EPN2, SH3GL1, CAV1, 
YWHAZ, STX7, COPZ1, SNX2, SNX1, EEA1, SNX3, ARF5, STX12, TMED2, 
ITGAV, RAC1, AP3D1, TMED10, VPS35, EHD1, HSPA8, HIP1, HCK, 
SCRN1, CORO1C, AP2A2, LRP1, VCP, AP2A1, RAB35, ARF4, MERTK, 
YKT6, MYH10, DNM2 
3.49E-05 
GO:0033043~regulation of 
organelle organization 
30 2.66E-
07 
XPO1, CAV1, LIMA1, PML, RDX, RCC1, CAPZB, TPM1, CTNNB1, PIN1, 
ACTR3, MACF1, ARPC2, RAC1, NPM1, RHOA, RANBP1, ARHGEF2, 
ROCK2, MAP1B, UBE2N, ARPC1A, ARPC1B, ARPC5L, GOLPH3, CAPG, 
MAP2, MAP4, SPTBN1, SPTAN1 
3.51E-05 
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GO:0032268~regulation of 
cellular protein metabolic 
process 
49 2.76E-
07 
NCBP1, METAP1, A2M, EIF5B, APP, PRKAR2A, NDUFS4, PSMD1, GAB1, 
PSMD3, PSMD6, PSMD9, PRKCA, PPP2R1A, LYN, UBE2N, EIF4G2, 
PSMA1, MAPK1, PSMA4, EIF2S1, F2, PSMA3, PSME3, CAV1, PTPLAD1, 
PML, IGF2BP2, IGF2BP3, PSMA7, GCN1L1, CALR, PIN1, PSMB7, PTK2B, 
ITGAV, PSMB3, DDX1, ITGA2, DOCK7, ETF1, YWHAE, EIF4B, HDAC2, 
PSMD12, PSMD11, BAX, PSMC1, PPP2R4 
3.49E-05 
GO:0006099~tricarboxylic 
acid cycle 
10 4.25E-
07 
SDHA, DLST, NNT, ACO2, SUCLG2, SUCLG1, CS, IDH2, IDH1, MDH1 5.14E-05 
GO:0046356~acetyl-CoA 
catabolic process 
10 4.25E-
07 
SDHA, DLST, NNT, ACO2, SUCLG2, SUCLG1, CS, IDH2, IDH1, MDH1 5.14E-05 
GO:0051443~positive 
regulation of ubiquitin-protein 
ligase activity 
16 5.57E-
07 
PSMA7, PIN1, UBE2N, PSMA1, PSMB7, PSMD12, PSMD11, PSMB3, 
PSMA4, PSMC1, PSMA3, PSMD1, PSMD3, PSME3, PSMD6, PSMD9 
6.47E-05 
GO:0006457~protein folding 26 6.25E-
07 
FKBP4, PDIA6, CCT2, CCT3, CALR, CANX, PIN1, ERO1L, HSPA8, 
DNAJA2, HSP90AA1, CRYAB, AARS, ERP29, ST13, TRAP1, HSP90B1, 
CCT5, CCT4, TBCA, PFDN5, TBCD, PPID, RUVBL2, FKBP10, AHSA1 
6.97E-05 
GO:0006605~protein 
targeting 
29 7.3E-
07 
XPO1, YWHAZ, NUP98, PML, AKAP12, CALR, CDC37, SSR1, MACF1, 
ZFYVE16, PPP3CA, SEC61A1, AP3B1, FYB, IPO9, YWHAE, MAPK1, 
ERBB2IP, TOMM70A, IPO7, GSK3B, F2, YWHAQ, KPNA6, SDCBP, 
SPTBN1, KPNA4, SRP72, XPO7 
7.85E-05 
GO:0006084~acetyl-CoA 
metabolic process 
11 7.8E-
07 
SDHA, DLST, NNT, ACO2, SUCLG2, SUCLG1, CS, IDH2, IDH1, DLAT, 
MDH1 
8.09E-05 
GO:0032269~negative 
regulation of cellular protein 
metabolic process 
26 8.6E-
07 
A2M, CAV1, PML, IGF2BP2, IGF2BP3, CALR, PSMA7, PSMB7, PSMB3, 
ITGAV, PSMD1, PSMD3, PSMD6, PSMD9, PRKCA, PPP2R1A, YWHAE, 
PSMA1, PSMD12, PSMD11, BAX, PSMA4, PSMC1, PSMA3, PSME3, 
PPP2R4 
8.61E-05 
GO:0007010~cytoskeleton 
organization 
45 9.69E-
07 
LIMA1, CAV1, TLN2, CALD1, ABI2, RCC1, CALR, TPM1, CAPZB, 
CTNNB1, ACTG1, CORO2B, PTK2, MACF1, PTK2B, NPM1, RAC1, RHOA, 
PAFAH1B1, RANBP1, DYNC1H1, FGD5, ARHGEF2, CAP2, ACTN4, 
CKAP5, ROCK2, CRYAB, MAP1B, ACTN1, DOCK7, MYH9, PALLD, FLNB, 
VASP, ARPC1A, EPB41L2, ERBB2IP, FGFR1OP, MAP2, SDCBP, CRK, 
LCP1, PARVA, MYH10 
9.37E-05 
GO:0051351~positive 
regulation of ligase activity 
16 9.87E-
07 
PSMA7, PIN1, UBE2N, PSMA1, PSMB7, PSMD12, PSMD11, PSMB3, 
PSMA4, PSMC1, PSMA3, PSMD1, PSMD3, PSME3, PSMD6, PSMD9 
9.24E-05 
GO:0008380~RNA splicing 34 1.08E-
06 
RALY, NCBP1, PRPF4B, STRAP, NHP2L1, SNRPD3, LSM7, RBM4, 
SNRPD1, SYNCRIP, SF3B3, PNN, PRPF19, SF3B1, DDX46, PRPF8, PCBP2, 
DNAJC8, NUDT21, USP39, DHX15, U2AF1, LSM3, PABPC1, PPP2R1A, 
EFTUD2, PTBP1, DDX1, SF1, MBNL1, SF3A1, PRPF4, SF3A3, SNRPC 
9.76E-05 
GO:0016044~membrane 
organization 
41 1.12E-
06 
CAV1, STX7, AP1B1, AP1G1, COPZ1, SNX2, SNX1, EEA1, EPS15L1, SNX3, 
CLTC, CD9, APP, PICALM, ITGAV, RAC1, PAFAH1B1, EHD1, SAR1B, 
HSPA8, HIP1, AP3B1, SEC23A, DNM1L, HSP90AA1, HCK, LMNA, 
CORO1C, AP2A2, LRP1, RAB18, AP2A1, TXNDC5, BAX, ARCN1, RAB5A, 
MERTK, SH3GL1, MYH10, EPN2, DNM2 
9.88E-05 
GO:0016071~mRNA 
metabolic process 
40 1.39E-
06 
RALY, NCBP1, PRPF4B, STRAP, NHP2L1, SNRPD3, RBM4, LSM7, 
SNRPD1, SYNCRIP, HNRPLL, SF3B3, PNN, PRPF19, SF3B1, APP, DDX46, 
PRPF8, PCBP2, NUDT21, DNAJC8, USP39, DHX15, U2AF1, LSM3, PABPC1, 
KHDRBS3, EFTUD2, PTBP1, DDX1, SF1, ELAVL1, MBNL1, SF3A1, PRPF4, 
SF3A3, CPSF6, SNRPC, XRN2, ADAR 
0.000118 
GO:0009109~coenzyme 
catabolic process 
10 1.43E-
06 
SDHA, DLST, NNT, ACO2, SUCLG2, SUCLG1, CS, IDH2, IDH1, MDH1 0.000119 
GO:0006396~RNA 
processing 
52 1.46E-
06 
RALY, NCBP1, PRPF4B, RPL14, SNRPD3, LSM7, RBM4, SNRPD1, 
SYNCRIP, SART3, HNRPLL, PNN, APP, DDX17, PCBP2, DNAJC8, U2AF1, 
LSM3, PPP2R1A, KHDRBS3, EFTUD2, PTBP1, AARS, SF1, MBNL1, PRPF4, 
RPS16, RPS14, CPSF6, SNRPC, XRN2, NHP2L1, STRAP, PABPC4, SF3B3, 
PRPF19, SF3B1, DDX46, PRPF8, NUDT21, USP39, DHX15, RPL5, RPL10A, 
PABPC1, NSUN2, RTCD1, DDX1, SMAD2, SF3A1, SF3A3, ADAR 
0.000118 
GO:0051248~negative 
regulation of protein 
metabolic process 
26 1.76E-
06 
A2M, CAV1, PML, IGF2BP2, IGF2BP3, CALR, PSMA7, PSMB7, PSMB3, 
ITGAV, PSMD1, PSMD3, PSMD6, PSMD9, PRKCA, PPP2R1A, YWHAE, 
PSMA1, PSMD12, PSMD11, BAX, PSMA4, PSMC1, PSMA3, PSME3, 
PPP2R4 
0.000138 
GO:0031400~negative 
regulation of protein 
modification process 
20 2.19E-
06 
PRKCA, PPP2R1A, CAV1, PSMA7, YWHAE, PSMA1, PSMB7, PSMD12, 
PSMD11, PSMB3, BAX, PSMA4, PSMD1, PSMC1, PSMA3, PSMD3, PSME3, 
PPP2R4, PSMD6, PSMD9 
0.000167 
GO:0051438~regulation of 
ubiquitin-protein ligase 
activity 
16 2.39E-
06 
PSMA7, PIN1, UBE2N, PSMA1, PSMB7, PSMD12, PSMD11, PSMB3, 
PSMA4, PSMC1, PSMA3, PSMD1, PSMD3, PSME3, PSMD6, PSMD9 
0.000178 
GO:0010033~response to 
organic substance 
62 3.43E-
06 
A2M, RBM4, DEK, B2M, CTNNB1, GOT2, ACTR3, HSPH1, PRKAR2A, 
GOT1, NDUFS4, CD44, GAB1, PRKCA, PPP2R1A, HSP90AA1, LYN, GATM, 
PFKL, CRYAB, AARS, CLIC1, MMP14, MAPK1, DDR1, GLUL, GNB1, 
0.000249 
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PDGFRA, ABAT, GNAS, COL1A1, EIF2AK2, PPP2R2A, PPP5C, CAV1, 
ADH5, PML, PRKDC, COMT, VARS, PTK2B, IDH1, PPP3CA, ERO1L, 
NUDC, HSPA8, MAP2K1, MSH2, MAP1B, ITGA2, SMAD2, ANXA5, STAT1, 
STAT3, PTPN11, GART, HDAC2, VCP, MAPK14, ALDH2, FABP4, PARP1 
GO:0051340~regulation of 
ligase activity 
16 3.92E-
06 
PSMA7, PIN1, UBE2N, PSMA1, PSMB7, PSMD12, PSMD11, PSMB3, 
PSMA4, PSMC1, PSMA3, PSMD1, PSMD3, PSME3, PSMD6, PSMD9 
0.000277 
GO:0070271~protein 
complex biogenesis 
48 3.97E-
06 
XPO1, PARD3, NUP98, CAV1, FKBP4, PML, CDH2, CALR, SF3B3, PXN, 
CTNNB1, FGG, PTK2, NDUFS4, PICALM, PTK2B, FGB, NPM1, RAC1, 
CAT, HIP1, PPP2R1A, HSP90AA1, MAP2K1, DARS, PFKL, CRYAB, EPRS, 
IPO9, SMAD2, DECR1, PFKM, ANXA5, SOD2, SPAG9, VCP, TBCA, 
UQCRH, IPO7, BAX, THRAP3, CAPG, RRM1, SMARCA5, LAMC1, XPO7, 
PARVA, PPP5C 
0.000275 
GO:0006461~protein 
complex assembly 
48 3.97E-
06 
XPO1, PARD3, NUP98, CAV1, FKBP4, PML, CDH2, CALR, SF3B3, PXN, 
CTNNB1, FGG, PTK2, NDUFS4, PICALM, PTK2B, FGB, NPM1, RAC1, 
CAT, HIP1, PPP2R1A, HSP90AA1, MAP2K1, DARS, PFKL, CRYAB, EPRS, 
IPO9, SMAD2, DECR1, PFKM, ANXA5, SOD2, SPAG9, VCP, TBCA, 
UQCRH, IPO7, BAX, THRAP3, CAPG, RRM1, SMARCA5, LAMC1, XPO7, 
PARVA, PPP5C 
0.000275 
GO:0006928~cell motion 46 4.01E-
06 
CALD1, PRKDC, ABI2, CDH2, TPM1, CAPZB, TPM4, VCL, ACTR3, 
ACTG1, GPX1, CD9, ACTR2, APP, PTK2, MACF1, CD44, ROBO1, ARPC2, 
PTK2B, RAC1, PAFAH1B1, TOP2B, FN1, PRKCA, MAP2K1, MSH2, 
PODXL, ANXA1, DPYSL5, ITGA2, MYH9, MMP14, VAV2, YWHAE, VASP, 
STAT3, ARPC1B, EPHA4, MAPK14, BAX, TXN, SDCBP, LAMC1, GAP43, 
MYH10 
0.000271 
GO:0031398~positive 
regulation of protein 
ubiquitination 
16 6.26E-
06 
PSMA7, PIN1, UBE2N, PSMA1, PSMB7, PSMD12, PSMD11, PSMB3, 
PSMA4, PSMC1, PSMA3, PSMD1, PSMD3, PSME3, PSMD6, PSMD9 
0.000413 
GO:0030029~actin filament-
based process 
29 7.03E-
06 
MYL6, LIMA1, CALD1, MYL1, ABI2, CALR, CAPZB, TPM1, ACTG1, 
CORO2B, PTK2B, RAC1, RHOA, PAFAH1B1, FGD5, ARHGEF2, ACTN4, 
ROCK2, ACTN1, MYH9, FLNB, VASP, EPB41L2, ARPC1A, SDCBP, CRK, 
LCP1, PARVA, MYH10 
0.000454 
GO:0051436~negative 
regulation of ubiquitin-protein 
ligase activity during mitotic 
cell cycle 
14 7.13E-
06 
PSMA7, PSMA1, PSMB7, PSMD12, PSMD11, PSMB3, PSMA4, PSMC1, 
PSMA3, PSMD1, PSMD3, PSME3, PSMD6, PSMD9 
0.00045 
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6. Potential drug pathways, as identified by surprisal analysis 
Utilizing String software 13 we examined protein-protein functional connectivity of the proteins influenced the 
most by the unbalanced processes (see for example Fig. S2, S4,S14 ,S15). To identify potential candidates for 
further research and/or targeted therapy we searched for the targets that had a relatively large number of protein-
protein connections according to String score (for more details see Figure legend of the Figure S2).  
The list below includes the main biological categories (as retrieved from GO and String) significantly involved in 
the unbalanced processes and suggested protein targets for further investigation. 
 
Constraint 1  :  hyperactive signaling in wt+  tumors due to 1  . Fig S2 and Table S2 indicate that pEGFR 
protein and its related downstream signaling play significant role in the 1  . 
Constraint 2  :  Elevated migration/cytoskeleton organization, MAPK signaling in EGFRvIII+ tumors due to  
2   (Table S3 and Fig.S4).  
Protein candidates:  pLyn (Src family), pPTK2B, pPxn, pCbl create a clear and very connected cluster (Fig. S4). 
This cluster is related to migration network according to Cell Migration Gateway database (by The Cell Migration 
Consortium (CMC), Nature Publishing Group (NPG)) as well as pSTAT3 and CD44.  
Constraint 3   (GBM15 and GBM10 vs GBM12): Increased RAS/MAPK signaling and migration in 
GBM15 and GBM10 due to 3   .  
GBM15 and GBM10 tumors possess unbalanced process comprised of a smaller cluster of migration proteins 
connected to the RAS/MAPK network and collagen proteins (TableS4). Protein candidates:  pMAPK1, 
pMAPK3, pPxn and pBCAR1. 
Constraint 4   (GBM39 vs GBM59): Enhanced aerobic glycolysis/Ras signaling in GBM59 and migration in 
GBM39 due to 4   . Migration network connected to PDGFR14,STAT115 and PLCγ 16 is induced in GBM39 
but not in GBM59. Thus additional potential proteins targets for GBM39 are: STAT1, pPLC and PDGFR  
(Fig.S14). Protein candidates for GBM 59 tumor (but not GBM39) will include proteins involved in aerobic 
glycolysis, such as ENO1, LDHA, pPKM2 (y105), pPI3K and also induced targets from the EGFR/MAPK 
pathway, such as MAPK1 and MAPK3 (Fig.S15 and Table S5). 
Constraint 5   (GBM6 vs GBM15): Enhanced glycolysis through oxidative phosphorylation and Ras  
signaling in GBM6  due 5  . Protein candidates for GBM 6 : multiple ATP synthases, aldolase A, LDHB, 
pMAPK3/1, pp38, pMAPK12. (Table S6). In GBM15 there is a significant increase in EGFR/MAPK signaling 
due to 5   in comparison with GBM6 (Table S6) 
Constraint 6   (GBM26 vs GBM8):  Enhanced migration/cytoskeleton organization in GBM26 and  
DNA packaging in GBM8 due to 6  .  
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 Protein targets/ pathways for further investigation are pWas, pYes, pLyn for GBM26 and multiple histones for 
GBM8 (Table S7). 
Constraint 7   (GBM6 vs GBM8, GBM26): induced EGFR signaling and glycolytic enzymes in GBM6 and 
DNA packaging in GBM8 due to 7  . 
Protein processes and protein candidates for GBM6:  pEGFR y1045/y1068 pathway and glycolysis and 
multiple histones in GBM8/GBM26 connected to the EGFR network (in this constraint EGFR protein expression 
levels, and not phosphorylation sites) are elevated in GBM8/GBM26 (Table S8). 
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7. Supplementary Figures 
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Figure S1. Sorted values of iG  from the unbalanced processes 1  and 2  . The proteins are not independent but 
are correlated due to the constraints since each given constraint influences a subset of proteins in a similar way by causing 
coordinated deviations  of protein levels (up or down ) from the basal level. All the proteins that had 0.03iG   or 
0 .03iG     (those that exceeded the 0 red box) were considered as influenced the most by the constraints 1,2  . 
Similarly for all other constraints  3,4..7  only proteins with  0.03iG   or 0 .03iG     were further analyzed. 
For every constraint we find that  levels of about 100 proteins deviate significantly in either the upper ( 0.03iG   )  or 
lower direction ( 0 .03iG    ) from the steady state .For many proteins the the extent of influence, iG , is about zero for 
1,2...7  ,  meaning that they are mostly players in the steady state (inside the 0 red box) . Only those proteins with the 
values 0.03iG    or  0.03iG     were included in the classification of biological categories using David database 5  
as reported in Tables S1-S8.  For example phospho- proteins were found to be  influenced the most by 1   and deviate in 
the same upper direction ( 0.03iG   ).Proteins that had the values 0.02 0.02iG     in all constraints were 
considered as influenced by the steady state and not influenced by any of the ongoing unbalanced processes.  
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Figure S2.Connectivity of the proteins influenced by the unbalanced process 1 . A String map, representing protein-
protein functional connectivity, was generating using String software for those proteins influenced by the unbalanced process 
1    ( 0.031Gi  values) and up-regulated in GBMwt+ and GBM EGFRvIII tumors due to 1 . The vast majority of the 
proteins are tyrosine-phosphorylated. The thickness of the edges reflects the approximate probability of the protein-protein 
functional link for the related proteins as provided by the String score (confidence score in STRING correspond to the 
probability of finding the linked proteins within the same KEGG pathway 13). Thick lines (as for EGFR and MAPK1 (red 
small circles), String score = 0.98) represent high probability for the functional connectivity based on biochemical 
verification.  
 
 
pEGFR 
Y992,y1045/1068,y1086 
EGFR 
signaling 
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Figure S3. Identification of regulatory constraint 1  . (a) Steady state expression levels opXi  for 192 phosphoproteins 
were computed using 0( )k  and 0iG parameters obtained from the analysis of the entire dataset (unmodified and 
phosphorylated proteins). (b) Influence of the constraint  1   on the phospho levels of the phosphoproteins, Xio  (  1), 
was calculated using ( )k  and iG  parameters (for 0,1  ) obtained  from the  analysis of the entire dataset. The sum 
Xi
o  (  1) was compared to the opXi  values from (d). (c) For every measured phosphoprotein the importance of the 
unbalanced process 1   is determined by comparison of the Xio  (  1)(blue curve), sum of the stable state and the 
1   deviation term, to the experimental phosphoprotein expression levels (black curves). This constraint is highly 
important in a large subset of the phosphorylated proteins. (d) Steady state expression levels opXi for 192 phosphoproteins 
were computed using 0( )k  and 0iG parameters obtained from the surprisal analysis of the subgroup of phosphorylated 
proteins (pGBM). When that subset is analyzed separately, the   1  constraint of the full data is found to become an 
integral part of the phospho steady state opXi . Addition of the first original constraint 1  to the original steady state 
expression levels (b) reproduces closely the opXi levels (d). Thus the first constraint 1  of the full data set can therefore 
be regarded as a regulatory constraint of the GBM system. 
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Figure S4.Connectivity of the proteins influenced by the unbalanced process 2 .A String map, representing protein-
protein functional connectivity, was generating using String software for the proteins influenced by the unbalanced process 
2   ( 0.032Gi  values) and up-regulated in GBM EGFRvIII tumors due to 2 . Potential drug targets are the hub 
proteins involved in ell migrations that have a big number of partners : pLyn, pPTK2B, pPxn,pCbl, pSTAT3 and CD44.  
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Figure. S5. Minor unbalanced processes 5,6,7   (a) GBM dependent steady state term, 0  , was calculated using 
either the original dataset including 8 GBM tumors (green plot) or only a subset of 4 GBM tumors (k =8,15,26,6, blue plot). 
(b) Amplitude ( )7 k  of the unbalanced process 7   from the original matrix (green plot) was compared to the 
amplitude ( )3 k , representing the unbalanced process 3   as obtained from a small matrix containing only 4 GBM 
tumors (blue plot). Similarity between two curves, that were calculated using different data sets as indicated above, points to 
the significance of the 7   constraint in the analysis and characterization of the GBM tumors. (c) Scatter plot represents 
extent of correlation between the 3Gi  values calculated for 3   using the smaller matrix and 7Gi  values obtained from 
the entire dataset. (d) pWAS and ATPJ2 are examples for the proteins influenced by the unbalanced processes 5,6,7  . 
Experimental protein expression levels (black curve) could be closely reproduced when for  pWAS  the 6   and 7    
deviation term was added to the sum ( 1)oiX    and for ATPJ2 the term 5   terms was added to the sum 
( 1)oiX    (blue curves), pointing to the significant influence of the constraints 5,6,7  on the protein expression 
levels of these proteins. 
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Figure S6. Minor constraints as identified using Surprisal analysis.  (a,c) Amplitude ( )5 k  of the unbalanced process 
5   (a) or amplitude ( )6 k  of the unbalanced process 6  (c) from the original matrix (green plots) were respectively 
compared to the amplitudes ( )1 k  and ( )2 k  that represent the unbalanced process 1  (a) and 2  (c) as obtained 
from a small matrix containing only 4 GBM tumors (blue plots). was calculated using either the original dataset including 8 
GBM tumors (green plot) or only a subset of 4 GBM tumors (k =8,15,26,6, blue plot). Similarity between two curves, that 
were calculated using different matrices as indicated above, points to the significance of the  5   and 6  constraints in 
the characterization of the GBM tumors. (b,d) Scatter plot representing extent of correlation between the 1Gi  values 
calculated for 1   using the smaller matrix and 5Gi  values obtained from the entire dataset (b) and between the 2Gi  
values calculated for 2   using the smaller matrix and 6Gi  values obtained from the entire dataset (d). 
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Figure S7. PCA analysis. (a-c) Representation of the measured protein data in the principal component space by Principal 
component scores. PC scores correspond to the eigenvectors of a smaller (8x8) matrix and represent coordination between 
GBM tumors. (a) Principal component scores 1 and 2 are presented via plotting PC1 vs PC2 (left panel) or PC1, PC2 vs 
tumor index (right panel). (b) Principal components scores 3 and 4. (c) Principal components scores 5,6 and 7. (d) Sorted 
values of the protein coefficients corresponding to the PC1 (protein coefficients corresponding to other principle components 
(PC2-PC7) are presented in the Additional Table SI (excel table) .Proteins inside the red box were considered as not 
contributing to the PC1. Same considerations were applied to other PCs . (e). Using PCA analysis 24 proteins contributing 
significantly to the PC1 were identified. 18 of them appeared to contribute to the unbalanced process 1  (constraint of 
phosphorylation, increased intensity in GBMwt+ and GBM EGFRVIII) as identified utilizing surprisal analysis. 6 other 
contributed to the 2  . (f). 28 out of the 35 proteins contributing significantly to the PC2 were found to contribute 
significantly to the 1  . 
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Figure S8. Principle components from PCA analysis using correlation matrix. Sorted values of the protein coefficients 
for the PC1 and PC2. Correlation matrix doesn’t allow clear identification of the proteins contributing to the Principal 
components.   
 
 
Figure S9. Summary of the GO categories associated with different PC (PC1-PC7). Notation + or – indicates the 
direction of change from the mean value. For example constraint PC =2 includes enhanced phosphorylation (P) in GBM15 
tumor (++). The size of the + / – and number of the signs reflect relative importance of a particular PC for that GBM tumor. 
This table is quite different from Figure 5 in particular because some proteins that deviate from the stable state in one 
direction are identified by PCA to deviate in an opposite direction from the mean or not to deviate. In part this is because 
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PCA is more sensitive to the higher variance of the phosphoproteins. Furthermore, some of the important biological 
categories, such as glycolysis through oxidative phosphorylation or DNA packaging were not identified in the PCA analysis.  
 
Figure S10. Silhouette evaluation plot.The silhouette value for each protein is a measure of how similar that protein is to 
proteins in its own cluster. A +1 value for the proteins in a given cluster would indicate that that cluster contains proteins 
with completely distinct biological behaviors relative other clusters.  For example, if the proteins in a cluster all exhibit 
positive and large Silhouette values, this implies a level of uniqueness to that cluster. By contrast, if many proteins in a 
cluster exhibit a small or negative silhouette value, then those proteins are not uniquely identified as distinct from 
neighboring clusters.  (a) k-means clustering using the entire dataset.  The majority of the proteins exhibit Silhouette values < 
0.2 . (b) k-means clustering using the subset of phosphoproteins. Here, almost >95% of the proteins exhibit a positive 
Silhouette value. Only those proteins with Silhouette values >0.2 were further analyzed.   
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Figure S11.K-means clustering algorithm. Analysis using k-means clustering using the subset of phosphorylated proteins. 
This analysis identified an optimal number of clusters as being near 10, meaning that this was the minimal number of clusters 
accounted for the majority of the phospho-proteins (>95% of the proteins had Silhouette values > 0)  .  An example of how 
this analysis is interpreted is as follows.  Cluster #7 contains about 33 phosphoproteins, and strongly influences GBM15. 
Those phosphoproteins were then analyzed using the Silhouette evaluation (Fig S6). Proteins with Silhouette values > 0.2 ,( 
26 proteins from Cluster #7), were included in further biological analysis. For these curves, only the centroids (centers of the 
clusters) are presented.  
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Figure S12. Comparison between non-normalized and normalized iTRAQ proteomic datasets. To show that 
normalization, in which protein intensity levels from GBM 12,15,26 and 59 were divided by the protein intensity levels from 
GBM8,don’t influence the constraints, surprisal analysis was performed using either normalized or non-normalized datasets. 
Figure S9 shows comparison between the results obtained from normalized or non-normalized  datasets.  (a, b) Amplitude
( )1 k  of the unbalanced process 1   (a) was calculated using non-normalized protein values for GBM 12, 8, 15, 26 and 
59. This constraint was compared to the 2   constraint as identified using a normalized dataset.  For that normalization, 
the protein intensity levels from GBM 12,15,26 and 59 were divided by the protein intensity levels from GBM8 (b) . (c) 
Scatter plot representing extent of correlation between the 2Gi  values calculated for 2   using the normalized dataset and 
1Gi  values obtained from the non-normalized dataset. (d, e) The amplitude ( )2 k  of the unbalanced process 2   (d) was 
calculated using non-normalized protein values for GBM 12, 8, 15, 26 and 59, and then again (e) following normalization 
with GBM8. Similar to figure parts a and b, this constraint was compared to the 1   constraint as identified using the 
normalized dataset. (f) Scatter plot representing extent of correlation between the 1Gi  values calculated for 1   using 
normalized dataset and 2Gi  values obtained from the non-normalized dataset. The unbalanced processes are the same in the 
normalized and  non-normalized datasets as expected.  
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Figure S13. Comparison between the unbalanced processes as identified using CGH and iTRAQ datasets.  (a, b) 
Amplitude ( )1 k  of the unbalanced process 1   as identified using CGH normalized dataset (a) was compared to the 
amplitude ( )1 k  as identified using iTRAQ dataset .(c,d) Sorted values of 1Gi from the CGH (c) and iTRAQ (d) datasets. All 
the genes that had 0.0151Gi    (encircled in blue oval)  or 0.0151Gi  were considered as influenced significantly by the 
1  constraint  and were compared to the list of the proteins with the values  0.031Gi   or 0.031Gi  correspondingly.  
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Figure S14.Connectivity of the proteins influenced by the unbalanced process 4 .A String map representing protein-
protein functional connectivity for the proteins influenced by the unbalanced process 4   ( 0.034Gi  values) and up-
regulated in GBM39 due to 4 . Potential candidates identified from the 4th are located in the red circle. 
Ras/MAPK 
signaling 
migration 
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Figure S15.Connectivity of the proteins influenced by the unbalanced process 4 . A String map representing protein-
protein functional connectivity for the proteins influenced by the unbalanced process 4   ( 0.034Gi   values) and up-
regulated in GBM59 due to 4 . Potential candidate processes in GBM59 are encircled in red. 
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8. Abbreviations  
EGFR - epidermal growth factor receptor 
EGFRvIII - EGFR variant(v)III oncoprotein 
p-STAT3- phospho(p)-Signal Transducer and Activator of Transcription3   
Abi2 - p-Abelson Interactor2  
pLyn -  phospho(p)-Lck-Yes-related novel tyrosine kinase 
pPLC- p-Phospholipase C 
CD44 - Cell Surface Glycoprotein 
pPxn  - p-paxillin 
pMAPK1,3 – p- Mitogen-Activated Protein Kinase 1,3 
pSRC – p- V-Src Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog pBCAR1- Breast Cancer 
Anti-Estrogen Resistance 1 
PTEN  - Phosphatase And Tensin Homolog  
pPI3K  - p-Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 
LDHA – lactate dehydrogenase A 
Ras  - Rat Sarcoma Viral Oncogene Homolog 
LDHB - lactate dehydrogenase B 
IDH2 - Isocitrate Dehydrogenase 2  
pP38  - p-Mitogen-Activated Protein Kinase 14  
p - phosphorylation 
pPKM2  - p-pyruvate kinase 
PCA - Principal component analysis  
GBM - glioblastoma multiforme 
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SVD- singular value decomposition 
iTRAQ - Isobaric tags for relative and absolute quantitation 
CGH - Comparative genomic hybridization 
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